WO2005007644A1 - ヘテロアリールオキシ含窒素飽和へテロ環誘導体 - Google Patents
ヘテロアリールオキシ含窒素飽和へテロ環誘導体 Download PDFInfo
- Publication number
- WO2005007644A1 WO2005007644A1 PCT/JP2004/009272 JP2004009272W WO2005007644A1 WO 2005007644 A1 WO2005007644 A1 WO 2005007644A1 JP 2004009272 W JP2004009272 W JP 2004009272W WO 2005007644 A1 WO2005007644 A1 WO 2005007644A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- lower alkyl
- yloxy
- pyrimidine
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 305
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 208000019116 sleep disease Diseases 0.000 claims abstract description 24
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims abstract description 20
- 229940125425 inverse agonist Drugs 0.000 claims abstract description 14
- 102100032508 Histamine H3 receptor Human genes 0.000 claims abstract description 9
- 101001016833 Homo sapiens Histamine H3 receptor Proteins 0.000 claims abstract description 9
- 208000008589 Obesity Diseases 0.000 claims abstract description 9
- 235000020824 obesity Nutrition 0.000 claims abstract description 9
- 208000020685 sleep-wake disease Diseases 0.000 claims abstract description 9
- 230000028327 secretion Effects 0.000 claims abstract description 6
- 230000003054 hormonal effect Effects 0.000 claims abstract description 5
- -1 alkanol group Chemical group 0.000 claims description 1093
- 125000000217 alkyl group Chemical group 0.000 claims description 344
- 125000005843 halogen group Chemical group 0.000 claims description 145
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 144
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 136
- 229910052757 nitrogen Inorganic materials 0.000 claims description 130
- 125000003545 alkoxy group Chemical group 0.000 claims description 128
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 105
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 105
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 87
- 125000004432 carbon atom Chemical group C* 0.000 claims description 85
- 125000003282 alkyl amino group Chemical group 0.000 claims description 73
- 125000000623 heterocyclic group Chemical group 0.000 claims description 73
- 238000002360 preparation method Methods 0.000 claims description 68
- 125000005195 alkyl amino carbonyloxy group Chemical group 0.000 claims description 66
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 61
- 125000003277 amino group Chemical group 0.000 claims description 57
- 125000001424 substituent group Chemical group 0.000 claims description 56
- 150000003951 lactams Chemical group 0.000 claims description 52
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 49
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 47
- 125000006239 protecting group Chemical group 0.000 claims description 46
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 44
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 43
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 41
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 39
- 125000001072 heteroaryl group Chemical group 0.000 claims description 38
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 125000002947 alkylene group Chemical group 0.000 claims description 27
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 206010022437 insomnia Diseases 0.000 claims description 26
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 22
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 22
- 125000001624 naphthyl group Chemical group 0.000 claims description 20
- 125000002252 acyl group Chemical group 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 17
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 16
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 16
- 230000007958 sleep Effects 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- WYANFTXHKVXPFJ-UHFFFAOYSA-N 1-cyclopentylpiperidine Chemical compound C1CCCC1N1CCCCC1 WYANFTXHKVXPFJ-UHFFFAOYSA-N 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 13
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 12
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims description 11
- 206010020772 Hypertension Diseases 0.000 claims description 11
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 11
- 206010015037 epilepsy Diseases 0.000 claims description 11
- 206010020765 hypersomnia Diseases 0.000 claims description 11
- 208000030159 metabolic disease Diseases 0.000 claims description 11
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 11
- 230000003252 repetitive effect Effects 0.000 claims description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 125000002971 oxazolyl group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 239000000470 constituent Substances 0.000 claims description 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 7
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 claims description 6
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims description 6
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 6
- 208000016588 Idiopathic hypersomnia Diseases 0.000 claims description 6
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 6
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 6
- 201000003631 narcolepsy Diseases 0.000 claims description 6
- 208000023515 periodic limb movement disease Diseases 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 201000002859 sleep apnea Diseases 0.000 claims description 6
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 208000007848 Alcoholism Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 208000032841 Bulimia Diseases 0.000 claims description 5
- 208000017164 Chronobiology disease Diseases 0.000 claims description 5
- 206010012218 Delirium Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 5
- 206010014418 Electrolyte imbalance Diseases 0.000 claims description 5
- 201000005569 Gout Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 208000026139 Memory disease Diseases 0.000 claims description 5
- 208000016285 Movement disease Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 201000007930 alcohol dependence Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 206010013663 drug dependence Diseases 0.000 claims description 5
- 208000010706 fatty liver disease Diseases 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 229960005181 morphine Drugs 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 208000035824 paresthesia Diseases 0.000 claims description 5
- 208000027232 peripheral nervous system disease Diseases 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 5
- 208000011117 substance-related disease Diseases 0.000 claims description 5
- 125000004434 sulfur atom Chemical group 0.000 claims description 5
- 229910052727 yttrium Inorganic materials 0.000 claims description 5
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 4
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 4
- 102000000543 Histamine Receptors Human genes 0.000 claims description 4
- 108010002059 Histamine Receptors Proteins 0.000 claims description 4
- 241001024304 Mino Species 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims description 4
- 208000015114 central nervous system disease Diseases 0.000 claims description 4
- 208000016097 disease of metabolism Diseases 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- RHRLGFPTYKGJPR-UHFFFAOYSA-N 1-cyclobutylpiperidine Chemical compound C1CCC1N1CCCCC1 RHRLGFPTYKGJPR-UHFFFAOYSA-N 0.000 claims description 3
- 125000004791 2-fluoroethoxy group Chemical group FCCO* 0.000 claims description 3
- AVUMRZVBUNTZHE-UHFFFAOYSA-N 4-pyrimidin-5-ylbenzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=CN=CN=C1 AVUMRZVBUNTZHE-UHFFFAOYSA-N 0.000 claims description 3
- 208000017194 Affective disease Diseases 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 3
- 208000013403 hyperactivity Diseases 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- UZGLIIJVICEWHF-UHFFFAOYSA-N octogen Chemical group [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)CN([N+]([O-])=O)C1 UZGLIIJVICEWHF-UHFFFAOYSA-N 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 239000011593 sulfur Chemical group 0.000 claims description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 3
- HXBBLZCUSKLXPR-UHFFFAOYSA-N 3-pyrimidin-5-ylquinoline Chemical compound C=1C2=CC=CC=C2N=CC=1C1=CN=CN=C1 HXBBLZCUSKLXPR-UHFFFAOYSA-N 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- HUDGXVOXXXJDMJ-UHFFFAOYSA-N 5-[4-(trifluoromethoxy)phenyl]pyrimidine Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN=CN=C1 HUDGXVOXXXJDMJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 claims 1
- MMWRGWQTAMNAFC-UHFFFAOYSA-N 1,2-dihydropyridine Chemical compound C1NC=CC=C1 MMWRGWQTAMNAFC-UHFFFAOYSA-N 0.000 claims 1
- IIDJDCCUWMRWFQ-UHFFFAOYSA-N 1-(4-pyrimidin-5-ylphenyl)ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1=CN=CN=C1 IIDJDCCUWMRWFQ-UHFFFAOYSA-N 0.000 claims 1
- XRBIEKVLAQTWEU-UHFFFAOYSA-N 2-(1-cyclopentylpiperidin-4-yl)oxy-5-(4-methylsulfonylphenyl)pyrimidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C=N1)=CN=C1OC1CCN(C2CCCC2)CC1 XRBIEKVLAQTWEU-UHFFFAOYSA-N 0.000 claims 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims 1
- GCUFFFZVZBAEGA-UHFFFAOYSA-N 4-[6-(1-cyclopentylpiperidin-4-yl)oxypyridin-3-yl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1C(C=N1)=CC=C1OC1CCN(C2CCCC2)CC1 GCUFFFZVZBAEGA-UHFFFAOYSA-N 0.000 claims 1
- FRPTVBMFZHOJAC-UHFFFAOYSA-N 4-pyrazin-2-ylbenzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=CN=CC=N1 FRPTVBMFZHOJAC-UHFFFAOYSA-N 0.000 claims 1
- 241000180579 Arca Species 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 claims 1
- WISJFYNVLUAWCO-UHFFFAOYSA-N N1=CN=CC(=C1)C1=CC=C(C=C1)N1C(OCC1)=O Chemical compound N1=CN=CC(=C1)C1=CC=C(C=C1)N1C(OCC1)=O WISJFYNVLUAWCO-UHFFFAOYSA-N 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 claims 1
- 206010013990 dysuria Diseases 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 125000000864 peroxy group Chemical group O(O*)* 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 6
- 230000005856 abnormality Effects 0.000 abstract description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 67
- 238000001819 mass spectrum Methods 0.000 description 65
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 42
- 238000004519 manufacturing process Methods 0.000 description 38
- 239000002253 acid Substances 0.000 description 36
- 239000000203 mixture Substances 0.000 description 33
- 229960001340 histamine Drugs 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 229940079593 drug Drugs 0.000 description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 23
- 239000000556 agonist Substances 0.000 description 22
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 22
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 239000003112 inhibitor Substances 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 17
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
- 229910052739 hydrogen Inorganic materials 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 description 14
- 102000004384 Histamine H3 receptors Human genes 0.000 description 14
- 108090000981 Histamine H3 receptors Proteins 0.000 description 14
- QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 13
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 13
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 10
- 125000002950 monocyclic group Chemical group 0.000 description 10
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 10
- 230000000144 pharmacologic effect Effects 0.000 description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 229940122931 Histamine H3 receptor inverse agonist Drugs 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 6
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 6
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 5
- 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 5
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 208000030814 Eating disease Diseases 0.000 description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 230000037007 arousal Effects 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 125000006267 biphenyl group Chemical group 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 229940000425 combination drug Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 235000014632 disordered eating Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000020595 eating behavior Effects 0.000 description 4
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000005446 heptyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 4
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012746 preparative thin layer chromatography Methods 0.000 description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- 229940044601 receptor agonist Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical group C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 description 4
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 3
- DVVGIUUJYPYENY-UHFFFAOYSA-N 1-methylpyridin-2-one Chemical compound CN1C=CC=CC1=O DVVGIUUJYPYENY-UHFFFAOYSA-N 0.000 description 3
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 3
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 125000004651 chloromethoxy group Chemical group ClCO* 0.000 description 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000006880 cross-coupling reaction Methods 0.000 description 3
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000003382 histamine H3 receptor agonist Substances 0.000 description 3
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 3
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 210000000211 third ventricle Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- HAQIRIMIVLFYIX-ZFWWWQNUSA-N (2s)-1-[(2s)-2-aminobutanoyl]-n-butyl-2,3-dihydroindole-2-carboxamide Chemical compound C1=CC=C2N(C(=O)[C@@H](N)CC)[C@H](C(=O)NCCCC)CC2=C1 HAQIRIMIVLFYIX-ZFWWWQNUSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 2
- QJLPWVUZFKETMK-LLVKDONJSA-N (5r)-1,5,7,9,11,14-hexahydroxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carboxylic acid Chemical compound O=C1C2=C(O)C=C(O)C=C2C(=O)C2=C1C(O)=C1C[C@@H](O)C(C=C(C(=C3O)C(O)=O)C)=C3C1=C2O QJLPWVUZFKETMK-LLVKDONJSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 description 2
- FIRXFHJQGIIJDB-UHFFFAOYSA-N 1-methyl-2,3-dihydroindole Chemical compound C1=CC=C2N(C)CCC2=C1 FIRXFHJQGIIJDB-UHFFFAOYSA-N 0.000 description 2
- KXIXHISTUVHOCY-UHFFFAOYSA-N 1-propan-2-ylpiperidine Chemical compound CC(C)N1CCCCC1 KXIXHISTUVHOCY-UHFFFAOYSA-N 0.000 description 2
- NFDFTMICKVDYLQ-UHFFFAOYSA-N 2-[2-[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-1,3-thiazol-2-yl]carbamoyl]-5,7-dimethylindol-1-yl]acetic acid Chemical compound C1=C(Cl)C(OC)=CC(C2=C(SC(NC(=O)C=3N(C4=C(C)C=C(C)C=C4C=3)CC(O)=O)=N2)CCC2CCCCC2)=C1OC NFDFTMICKVDYLQ-UHFFFAOYSA-N 0.000 description 2
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 2
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 2
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 2
- CALMMRTVGPFXAM-UHFFFAOYSA-N 4-(6-fluoropyridin-3-yl)benzonitrile Chemical compound C1=NC(F)=CC=C1C1=CC=C(C#N)C=C1 CALMMRTVGPFXAM-UHFFFAOYSA-N 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- CCMRFUCSFRRPNT-UHFFFAOYSA-N 4-pyridin-2-ylbenzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=CC=CC=N1 CCMRFUCSFRRPNT-UHFFFAOYSA-N 0.000 description 2
- XPGIBDJXEVAVTO-UHFFFAOYSA-N 5-bromo-2-chloropyrimidine Chemical compound ClC1=NC=C(Br)C=N1 XPGIBDJXEVAVTO-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- NBLJURWIDNCFGJ-UHFFFAOYSA-N C1(CCC1)N1CC=CC=C1 Chemical compound C1(CCC1)N1CC=CC=C1 NBLJURWIDNCFGJ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
- 101710150887 Cholecystokinin A Proteins 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 101000809257 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 4 Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- QJLPWVUZFKETMK-UHFFFAOYSA-N Pradimicin Q Natural products O=C1C2=C(O)C=C(O)C=C2C(=O)C2=C1C(O)=C1CC(O)C(C=C(C(=C3O)C(O)=O)C)=C3C1=C2O QJLPWVUZFKETMK-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102100038463 Ubiquitin carboxyl-terminal hydrolase 4 Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000005103 alkyl silyl group Chemical group 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
- 229960002604 colestipol Drugs 0.000 description 2
- 230000037011 constitutive activity Effects 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 125000005202 dialkylaminocarbonyloxy group Chemical group 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000004590 drinking behavior Effects 0.000 description 2
- UNBMQQNYLCPCHS-VYNDPHDASA-N ebelactone b Chemical compound CC[C@@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)\C=C(/C)C[C@H](C)[C@@H]1OC(=O)[C@H]1CC UNBMQQNYLCPCHS-VYNDPHDASA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000000742 histaminergic effect Effects 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000005555 hypertensive agent Substances 0.000 description 2
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 2
- 229960004569 indapamide Drugs 0.000 description 2
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 2
- 229950008838 indenolol Drugs 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960003963 manidipine Drugs 0.000 description 2
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960003938 moxonidine Drugs 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 210000002970 posterior hypothalamus Anatomy 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 125000006308 propyl amino group Chemical group 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000001226 reprecipitation Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- 239000003451 thiazide diuretic agent Substances 0.000 description 2
- 229910052718 tin Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- REZGGXNDEMKIQB-UHFFFAOYSA-N zaprinast Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 description 2
- 229950005371 zaprinast Drugs 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- BHVGOYREXHCFOE-DCFHFQCYSA-N (1r,2s)-2-[2-(5,6-dihydrodibenzo[1,2-a:1',2'-e][7]annulen-11-ylidene)ethyl-methylamino]-1-phenylpropan-1-ol Chemical compound C1([C@@H](O)[C@H](C)N(C)CC=C2C3=CC=CC=C3CCC3=CC=CC=C32)=CC=CC=C1 BHVGOYREXHCFOE-DCFHFQCYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LPUDGHQMOAHMMF-JBACZVJFSA-N (2s)-2-[[[(2s)-6-amino-2-(methanesulfonamido)hexanoyl]amino]methyl]-3-[1-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]cyclopentyl]propanoic acid Chemical compound N([C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)C1(C[C@@H](CNC(=O)[C@H](CCCCN)NS(=O)(=O)C)C(O)=O)CCCC1 LPUDGHQMOAHMMF-JBACZVJFSA-N 0.000 description 1
- ZXEIEKDGPVTZLD-NDEPHWFRSA-N (2s)-2-dodecylsulfanyl-n-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetamide Chemical compound O=C([C@@H](SCCCCCCCCCCCC)C=1C=CC=CC=1)NC1=CC(C)=C(O)C(C)=C1C ZXEIEKDGPVTZLD-NDEPHWFRSA-N 0.000 description 1
- RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 description 1
- YDIKCZBMBPOGFT-DIONPBRTSA-N (2s,3r,4s,5s,6r)-2-[5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)chromenylium-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride Chemical compound [Cl-].COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 YDIKCZBMBPOGFT-DIONPBRTSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- PFMXXIJBGKRAJY-ITMZJIMRSA-N (3s)-4-[[(2s)-3-carboxy-1-oxo-1-(2-phenylethoxy)propan-2-yl]amino]-3-[6-[[(2s)-3-(1h-indol-3-yl)-2-[[2-[6-[[(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-sulfooxyphenyl)propanoyl]amino]hexanoylamino]acetyl]amino]propanoyl]amino]hexanoylamino]-4-oxob Chemical compound C([C@H](NC(=O)OC(C)(C)C)C(=O)NCCCCCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCCCCCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)OCCC=1C=CC=CC=1)C1=CC=C(OS(O)(=O)=O)C=C1 PFMXXIJBGKRAJY-ITMZJIMRSA-N 0.000 description 1
- YGPZWPHDULZYFR-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-amine Chemical compound C1C=C2C[C@@H](N)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 YGPZWPHDULZYFR-DPAQBDIFSA-N 0.000 description 1
- CEBAHYWORUOILU-UHFFFAOYSA-N (4-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=C(C#N)C=C1 CEBAHYWORUOILU-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- RWNNRGBCWXOVAC-UHFFFAOYSA-N 1,4-bis[bis(aziridin-1-yl)phosphoryl]piperazine Chemical compound C1CN1P(N1CCN(CC1)P(=O)(N1CC1)N1CC1)(=O)N1CC1 RWNNRGBCWXOVAC-UHFFFAOYSA-N 0.000 description 1
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 1
- DTLGHRKVCXMBLU-UHFFFAOYSA-N 1-(2,2-difluoroethyl)pyridin-2-one Chemical compound FC(F)CN1C=CC=CC1=O DTLGHRKVCXMBLU-UHFFFAOYSA-N 0.000 description 1
- ZWOYGCPJYXFRFO-UHFFFAOYSA-N 1-(2-fluoroethyl)pyridin-2-one Chemical compound FCCN1C=CC=CC1=O ZWOYGCPJYXFRFO-UHFFFAOYSA-N 0.000 description 1
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 1
- QXKZYKFVUJEGTM-UHFFFAOYSA-N 1-[4-(2-cyclopropyloxyethyl)phenoxy]-3-(dimethylamino)propan-2-ol Chemical compound C1=CC(OCC(O)CN(C)C)=CC=C1CCOC1CC1 QXKZYKFVUJEGTM-UHFFFAOYSA-N 0.000 description 1
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- OHFWIMZWEJXIAU-UHFFFAOYSA-N 1-cyclopentyl-2H-pyridine Chemical compound C1(CCCC1)N1CC=CC=C1 OHFWIMZWEJXIAU-UHFFFAOYSA-N 0.000 description 1
- KJMYBDCXKKGIHT-UHFFFAOYSA-N 1-cyclopentylpiperidin-4-ol Chemical compound C1CC(O)CCN1C1CCCC1 KJMYBDCXKKGIHT-UHFFFAOYSA-N 0.000 description 1
- 125000006433 1-ethyl cyclopropyl group Chemical group [H]C([H])([H])C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- UCRIXEWTILHNCG-UHFFFAOYSA-N 1-ethyl-2h-pyridine Chemical compound CCN1CC=CC=C1 UCRIXEWTILHNCG-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- MTSQHZHIEDRSOM-UHFFFAOYSA-N 1-ethylpyridin-2-one Chemical compound CCN1C=CC=CC1=O MTSQHZHIEDRSOM-UHFFFAOYSA-N 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- TXQAZWIBPGKHOX-UHFFFAOYSA-N 1H-indol-3-amine Chemical compound C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000003070 2-(2-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- MTJUELTVQKBEPR-UHFFFAOYSA-N 2-(chloromethyl)oxetane Chemical compound ClCC1CCO1 MTJUELTVQKBEPR-UHFFFAOYSA-N 0.000 description 1
- LUZDYPLAQQGJEA-UHFFFAOYSA-N 2-Methoxynaphthalene Chemical compound C1=CC=CC2=CC(OC)=CC=C21 LUZDYPLAQQGJEA-UHFFFAOYSA-N 0.000 description 1
- TYZQFNOLWJGHRZ-UHFFFAOYSA-N 2-[2-(4,5-dihydro-1h-imidazol-2-yl)-1-phenylethyl]pyridine Chemical compound N=1CCNC=1CC(C=1N=CC=CC=1)C1=CC=CC=C1 TYZQFNOLWJGHRZ-UHFFFAOYSA-N 0.000 description 1
- ZGGNJJJYUVRADP-ACJLOTCBSA-N 2-[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(Cl)C=CC=1)C1=CC=C(OCC(O)=O)C=C1 ZGGNJJJYUVRADP-ACJLOTCBSA-N 0.000 description 1
- YMWJDWJXIXITMD-UHFFFAOYSA-N 2-[4-[3-[2-(2-chloro-6-fluorophenyl)ethyl-[(2,3-dichlorophenyl)carbamoyl]amino]propyl]phenoxy]-2-methylpropanoic acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCCN(C(=O)NC=1C(=C(Cl)C=CC=1)Cl)CCC1=C(F)C=CC=C1Cl YMWJDWJXIXITMD-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
- IHBAVXVTGLANPI-QMMMGPOBSA-N 2-amino-3-methyl-1-pyrrolidin-1-yl-butan-1-one Chemical compound CC(C)[C@H](N)C(=O)N1CCCC1 IHBAVXVTGLANPI-QMMMGPOBSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical group CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- BJNYOCHWLQCDHC-UHFFFAOYSA-N 2-fluorooxetane Chemical compound FC1CCO1 BJNYOCHWLQCDHC-UHFFFAOYSA-N 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- SXKBTDJJEQQEGE-UHFFFAOYSA-N 3-(3,5-dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonic acid [4-(thiazol-2-ylsulfamoyl)-phenyl]-amide Chemical compound CCC=1OC2=CC(S(=O)(=O)NC=3C=CC(=CC=3)S(=O)(=O)NC=3SC=CN=3)=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 SXKBTDJJEQQEGE-UHFFFAOYSA-N 0.000 description 1
- WZFZJEPHYDDFCT-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCN2C(COCC2)=O)=CS1 WZFZJEPHYDDFCT-UHFFFAOYSA-N 0.000 description 1
- ZYGLLHJTMNMFJS-UHFFFAOYSA-N 3-fluorooxolane Chemical compound FC1CCOC1 ZYGLLHJTMNMFJS-UHFFFAOYSA-N 0.000 description 1
- 125000001137 3-hydroxypropoxy group Chemical group [H]OC([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- XTFPDGZNWTZCMF-DHZHZOJOSA-N 3-o-methyl 5-o-[(e)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 XTFPDGZNWTZCMF-DHZHZOJOSA-N 0.000 description 1
- HEKNIPLMGLOMOP-UHFFFAOYSA-N 4-(6-oxo-1h-pyridazin-3-yl)benzonitrile Chemical compound N1C(=O)C=CC(C=2C=CC(=CC=2)C#N)=N1 HEKNIPLMGLOMOP-UHFFFAOYSA-N 0.000 description 1
- IUPSGHJPDSFGIV-UHFFFAOYSA-N 4-[2-(1-cyclopentylpyrrolidin-3-yl)oxypyrimidin-5-yl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1C(C=N1)=CN=C1OC1CN(C2CCCC2)CC1 IUPSGHJPDSFGIV-UHFFFAOYSA-N 0.000 description 1
- NZHVJPBBHJIWKI-UHFFFAOYSA-N 4-[2-(1-ethylpiperidin-4-yl)oxypyrimidin-5-yl]benzonitrile Chemical compound C1CN(CC)CCC1OC1=NC=C(C=2C=CC(=CC=2)C#N)C=N1 NZHVJPBBHJIWKI-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- NLPHXWGWBKZSJC-UHFFFAOYSA-N 4-acetylbenzonitrile Chemical compound CC(=O)C1=CC=C(C#N)C=C1 NLPHXWGWBKZSJC-UHFFFAOYSA-N 0.000 description 1
- SSLMGOKTIUIZLY-UHFFFAOYSA-N 4-bromo-1h-pyridin-2-one Chemical compound OC1=CC(Br)=CC=N1 SSLMGOKTIUIZLY-UHFFFAOYSA-N 0.000 description 1
- QKZHLBZNEBCOLM-UHFFFAOYSA-N 4-bromo-2-(difluoromethoxy)pyridine Chemical compound FC(F)OC1=CC(Br)=CC=N1 QKZHLBZNEBCOLM-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- IGIWPHRUBXKMAR-UHFFFAOYSA-N 4-cyclopropylphenol Chemical compound C1=CC(O)=CC=C1C1CC1 IGIWPHRUBXKMAR-UHFFFAOYSA-N 0.000 description 1
- ISFRSMMUUQWJCU-UHFFFAOYSA-N 4-hydroxy-1-methylpyridin-2-one Chemical compound CN1C=CC(O)=CC1=O ISFRSMMUUQWJCU-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- KQKFQBTWXOGINC-UHFFFAOYSA-N 4-phenylpiperidin-4-ol Chemical compound C=1C=CC=CC=1C1(O)CCNCC1 KQKFQBTWXOGINC-UHFFFAOYSA-N 0.000 description 1
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 1
- ITTXBHQAWOFJAI-UHFFFAOYSA-N 5-bromo-1h-pyrazin-2-one Chemical compound BrC1=CNC(=O)C=N1 ITTXBHQAWOFJAI-UHFFFAOYSA-N 0.000 description 1
- MYUQKYGWKHTRPG-UHFFFAOYSA-N 5-bromo-2-fluoropyridine Chemical compound FC1=CC=C(Br)C=N1 MYUQKYGWKHTRPG-UHFFFAOYSA-N 0.000 description 1
- GYCPLYCTMDTEPU-UHFFFAOYSA-N 5-bromopyrimidine Chemical compound BrC1=CN=CN=C1 GYCPLYCTMDTEPU-UHFFFAOYSA-N 0.000 description 1
- VPQICCOHFSGBMA-UHFFFAOYSA-N 5-bromopyrimidine-2-carbonitrile Chemical compound BrC1=CN=C(C#N)N=C1 VPQICCOHFSGBMA-UHFFFAOYSA-N 0.000 description 1
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 1
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- PTEFNEALEPSHLC-UHFFFAOYSA-N 6-bromopyridin-3-ol Chemical compound OC1=CC=C(Br)N=C1 PTEFNEALEPSHLC-UHFFFAOYSA-N 0.000 description 1
- QBFRPGRSZWPABV-UHFFFAOYSA-N 6-fluoro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O QBFRPGRSZWPABV-UHFFFAOYSA-N 0.000 description 1
- FJNCXZZQNBKEJT-UHFFFAOYSA-N 8beta-hydroxymarrubiin Natural products O1C(=O)C2(C)CCCC3(C)C2C1CC(C)(O)C3(O)CCC=1C=COC=1 FJNCXZZQNBKEJT-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 241000251169 Alopias vulpinus Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710171801 Alpha-amylase inhibitor Proteins 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 1
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 description 1
- 101000782621 Bacillus subtilis (strain 168) Biotin carboxylase 2 Proteins 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 102100038495 Bile acid receptor Human genes 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 102100028628 Bombesin receptor subtype-3 Human genes 0.000 description 1
- RHLJLALHBZGAFM-UHFFFAOYSA-N Bunazosinum Chemical compound C1CN(C(=O)CCC)CCCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 RHLJLALHBZGAFM-UHFFFAOYSA-N 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- CUBGUDOSDBKVII-FHAQVOQBSA-O CC[C@H](C)[C@@H](C(O)=O)[NH3+].[C-]1=NC=CS1 Chemical compound CC[C@H](C)[C@@H](C(O)=O)[NH3+].[C-]1=NC=CS1 CUBGUDOSDBKVII-FHAQVOQBSA-O 0.000 description 1
- PHKYGBHARUTZOY-UHFFFAOYSA-N CKD-711 Natural products OC1C(O)C(NC2C(C(O)C(O)C3(CO)OC32)O)C(CO)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O PHKYGBHARUTZOY-UHFFFAOYSA-N 0.000 description 1
- 101100215147 Caenorhabditis elegans aco-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 229940127193 DGAT1 inhibitor Drugs 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016862 Dicarboxylic Acid Transporters Human genes 0.000 description 1
- 108010092943 Dicarboxylic Acid Transporters Proteins 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 229930188669 Ebelactone Natural products 0.000 description 1
- WOISDAHQBUYEAF-UHFFFAOYSA-N Ebelactone A Natural products CCC(C)C(O)C(C)C(=O)C(C)C=C(C)CC(C)C1OC(=O)C1C WOISDAHQBUYEAF-UHFFFAOYSA-N 0.000 description 1
- UNBMQQNYLCPCHS-UHFFFAOYSA-N Ebelactone B Natural products CCC(C)C(O)C(C)C(=O)C(C)C=C(C)CC(C)C1OC(=O)C1CC UNBMQQNYLCPCHS-UHFFFAOYSA-N 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 108010087894 Fatty acid desaturases Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- QTQMRBZOBKYXCG-MHZLTWQESA-N GW 1929 Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCN(C)C=1N=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 QTQMRBZOBKYXCG-MHZLTWQESA-N 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000000028 HMX Substances 0.000 description 1
- 241000412298 Harma Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229940121914 Histamine H3 receptor agonist Drugs 0.000 description 1
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 description 1
- 101000588130 Homo sapiens Microsomal triglyceride transfer protein large subunit Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229940122439 Hydroxylase inhibitor Drugs 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000011145 Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
- 108010062875 Hydroxysteroid Dehydrogenases Proteins 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 101710186630 Insulin-1 Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 108700040553 JMV 180 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 101150106280 Mchr1 gene Proteins 0.000 description 1
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 description 1
- 108700036626 Melanin-concentrating hormone receptor 1 Proteins 0.000 description 1
- 102000001796 Melanocortin 4 receptors Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000907681 Morpho Species 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- HRRBJVNMSRJFHQ-UHFFFAOYSA-N Naftopidil Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C3=CC=CC=C3C=CC=2)CC1 HRRBJVNMSRJFHQ-UHFFFAOYSA-N 0.000 description 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 208000031964 Other metabolic disease Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229940126033 PPAR agonist Drugs 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 241000577218 Phenes Species 0.000 description 1
- URMXYPLWYMOYPG-UHFFFAOYSA-N Pipemidic acid trihydrate Chemical compound O.O.O.N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 URMXYPLWYMOYPG-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241001417524 Pomacanthidae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000005477 Pratosartan Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 101800000789 Protease-polymerase p70 Proteins 0.000 description 1
- 101800000786 Protease-polymerase p76 Proteins 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229940123185 Squalene epoxidase inhibitor Drugs 0.000 description 1
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HTWFXPCUFWKXOP-UHFFFAOYSA-N Tertatalol Chemical compound C1CCSC2=C1C=CC=C2OCC(O)CNC(C)(C)C HTWFXPCUFWKXOP-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 229930186167 Trestatin Natural products 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 101150046432 Tril gene Proteins 0.000 description 1
- 102000008318 Type 3 Melanocortin Receptor Human genes 0.000 description 1
- 108010021433 Type 3 Melanocortin Receptor Proteins 0.000 description 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
- IMIPDPVHGGHVNH-YWVHRCQQSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] (z)-octadec-9-enoate Chemical compound C1C[C@]2(C)C(=O)CC[C@H]2[C@@H]2CCC3=CC(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC=C3[C@H]21 IMIPDPVHGGHVNH-YWVHRCQQSA-N 0.000 description 1
- QDPOOGQUCJJZAO-FCXRPNKRSA-N [(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QDPOOGQUCJJZAO-FCXRPNKRSA-N 0.000 description 1
- HUOFUOCSQCYFPW-UHFFFAOYSA-N [4-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OC(F)(F)F)C=C1 HUOFUOCSQCYFPW-UHFFFAOYSA-N 0.000 description 1
- WOWJOKXMWINKBA-UHFFFAOYSA-N [5-[2-(1-cyclopentylpiperidin-4-yl)oxypyrimidin-5-yl]pyridin-2-yl]-pyrrolidin-1-ylmethanone Chemical compound C=1C=C(C=2C=NC(OC3CCN(CC3)C3CCCC3)=NC=2)C=NC=1C(=O)N1CCCC1 WOWJOKXMWINKBA-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002404 acyltransferase inhibitor Substances 0.000 description 1
- COAIBTZEXXESAS-TZSLYBJXSA-N adiposin Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1N[C@@H]1[C@H](O)[C@@H](O)[C@H](O)C(CO)=C1 COAIBTZEXXESAS-TZSLYBJXSA-N 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 125000005277 alkyl imino group Chemical group 0.000 description 1
- HUMHYXGDUOGHTG-HEZXSMHISA-N alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)OC1O HUMHYXGDUOGHTG-HEZXSMHISA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000008430 aponin Substances 0.000 description 1
- BHIAIPWSVYSKJS-UHFFFAOYSA-N arotinolol Chemical compound S1C(SCC(O)CNC(C)(C)C)=NC(C=2SC(=CC=2)C(N)=O)=C1 BHIAIPWSVYSKJS-UHFFFAOYSA-N 0.000 description 1
- 229950010731 arotinolol Drugs 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 229950010046 avasimibe Drugs 0.000 description 1
- 108010014210 axokine Proteins 0.000 description 1
- 229950004646 azelnidipine Drugs 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- 229960003665 bepridil Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 108010063504 bombesin receptor subtype 3 Proteins 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960002467 bunazosin Drugs 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 229910002090 carbon oxide Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical group OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- PHKYGBHARUTZOY-KTVVNDHVSA-N ckd-711 Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@]2(CO)O[C@@H]21)O)CO)[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O PHKYGBHARUTZOY-KTVVNDHVSA-N 0.000 description 1
- 229960003597 clevidipine Drugs 0.000 description 1
- KPBZROQVTHLCDU-GOSISDBHSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 229960002944 cyclofenil Drugs 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000001177 cyclohexylbutoxy group Chemical group [H]C([H])(O*)C([H])([H])C([H])([H])C([H])([H])C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003793 cyclohexylpropoxy group Chemical group [H]C([H])(O*)C([H])([H])C([H])([H])C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 229960005227 delapril Drugs 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 description 1
- GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 1
- 229960005081 diclofenamide Drugs 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical group C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- XHHVVCGGIPSCSN-UHFFFAOYSA-N diphenylphosphane;palladium Chemical compound [Pd].C=1C=CC=CC=1PC1=CC=CC=C1.C=1C=CC=CC=1PC1=CC=CC=C1 XHHVVCGGIPSCSN-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- ODUOJXZPIYUATO-LJQANCHMSA-N ecadotril Chemical compound C([C@H](CSC(=O)C)C(=O)NCC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 ODUOJXZPIYUATO-LJQANCHMSA-N 0.000 description 1
- 229950001184 ecadotril Drugs 0.000 description 1
- 229950005925 eflucimibe Drugs 0.000 description 1
- 229950003102 efonidipine Drugs 0.000 description 1
- 229950000269 emiglitate Drugs 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002792 enkephalinase inhibitor Substances 0.000 description 1
- 230000001787 epileptiform Effects 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- XXRVYAFBUDSLJX-UHFFFAOYSA-N etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 description 1
- 229960003501 etofibrate Drugs 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000005817 fluorobutyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical group C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- GZKDXUIWCNCNBJ-UHFFFAOYSA-N glisolamide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NC2CCCCC2)=N1 GZKDXUIWCNCNBJ-UHFFFAOYSA-N 0.000 description 1
- 229950005319 glisolamide Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- RVXLYPSYVXXSQE-UHFFFAOYSA-N hept-6-en-2-ol Chemical compound CC(O)CCCC=C RVXLYPSYVXXSQE-UHFFFAOYSA-N 0.000 description 1
- 108010070965 hexarelin Proteins 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- HPMRFMKYPGXPEP-UHFFFAOYSA-N idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 description 1
- 229950001476 idazoxan Drugs 0.000 description 1
- 229960001195 imidapril Drugs 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- KSMAGQUYOIHWFS-UHFFFAOYSA-N lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 description 1
- 229960005209 lofexidine Drugs 0.000 description 1
- 229940063720 lopid Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229940045623 meridia Drugs 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000006626 methoxycarbonylamino group Chemical group 0.000 description 1
- ZFLBZHXQAMUEFS-KUHUBIRLSA-N methyl 2-[4-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=CC(Cl)=C1 ZFLBZHXQAMUEFS-KUHUBIRLSA-N 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 229950001332 midaglizole Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 230000000407 monoamine reuptake Effects 0.000 description 1
- VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 description 1
- TUYWTLTWNJOZNY-UHFFFAOYSA-N n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2h-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2C=C(N=CC=2)C2=NNN=N2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)C)C=N1 TUYWTLTWNJOZNY-UHFFFAOYSA-N 0.000 description 1
- DIQDKUNCSVFGHH-UHFFFAOYSA-N n-[[4-[[(4-aminoquinazolin-2-yl)amino]methyl]cyclohexyl]methyl]naphthalene-1-sulfonamide;hydrochloride Chemical compound Cl.C1=CC=C2C(N)=NC(NCC3CCC(CNS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)CC3)=NC2=C1 DIQDKUNCSVFGHH-UHFFFAOYSA-N 0.000 description 1
- 229950005705 naftopidil Drugs 0.000 description 1
- 229960005297 nalmefene Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- YJMNOKOLADGBKA-UHFFFAOYSA-N naphthalene-1-carbonitrile Chemical compound C1=CC=C2C(C#N)=CC=CC2=C1 YJMNOKOLADGBKA-UHFFFAOYSA-N 0.000 description 1
- AZKDTTQQTKDXLH-UHFFFAOYSA-N naphthalene-2-carbonitrile Chemical compound C1=CC=CC2=CC(C#N)=CC=C21 AZKDTTQQTKDXLH-UHFFFAOYSA-N 0.000 description 1
- 208000004461 narcolepsy 1 Diseases 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- 125000005484 neopentoxy group Chemical group 0.000 description 1
- 125000005933 neopentyloxycarbonyl group Chemical group 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229950000754 nipradilol Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical group [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 1
- 229960001073 nomifensine Drugs 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
- 229950000973 omapatrilat Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 108700027320 pegylated leptin Proteins 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 125000006634 pentyloxycarbonylamino group Chemical group 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WCNCPULYBPXOKQ-UHFFFAOYSA-N phenyl 2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]oxypyrimidine-5-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=C(C(=O)OC=2C=CC=CC=2)C=N1 WCNCPULYBPXOKQ-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- IRWXYFWBGITFAG-UHFFFAOYSA-N piperidin-4-yl methanesulfonate Chemical compound CS(=O)(=O)OC1CCNCC1 IRWXYFWBGITFAG-UHFFFAOYSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229950004891 pranidipine Drugs 0.000 description 1
- 229950005649 pratosartan Drugs 0.000 description 1
- KCTFTBCZZUBAKN-UHFFFAOYSA-N pratosartan Chemical compound CCCC1=NC=2CCCCC(=O)C=2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 KCTFTBCZZUBAKN-UHFFFAOYSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 108010040933 progressin Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006628 propoxycarbonylamino group Chemical group 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 125000004673 propylcarbonyl group Chemical group 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 1
- 229940073095 questran Drugs 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- FLSLEGPOVLMJMN-YSSFQJQWSA-N quinaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)C(O)=O)CC1=CC=CC=C1 FLSLEGPOVLMJMN-YSSFQJQWSA-N 0.000 description 1
- 229960001007 quinaprilat Drugs 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 108700040249 racecadotril Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 239000002469 receptor inverse agonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- 229960003015 rimonabant Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 229950001780 sampatrilat Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000037322 slow-wave sleep Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229950001790 tendamistat Drugs 0.000 description 1
- 108010037401 tendamistate Proteins 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CTGDSCTYXKZUOI-UHFFFAOYSA-N tert-butyl 4-(5-bromopyrazin-2-yl)oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CN=C(Br)C=N1 CTGDSCTYXKZUOI-UHFFFAOYSA-N 0.000 description 1
- KLTCZRRLCMAACH-UHFFFAOYSA-N tert-butyl 4-[5-(2-cyanopyrimidin-5-yl)pyrimidin-2-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=C(C=2C=NC(=NC=2)C#N)C=N1 KLTCZRRLCMAACH-UHFFFAOYSA-N 0.000 description 1
- PKJMBIGPMJLPIP-UHFFFAOYSA-N tert-butyl 4-[5-(4-cyanophenyl)pyrimidin-2-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=C(C=2C=CC(=CC=2)C#N)C=N1 PKJMBIGPMJLPIP-UHFFFAOYSA-N 0.000 description 1
- LQWKFZXJUBAHSR-UHFFFAOYSA-N tert-butyl 4-[5-[4-(3-oxomorpholin-4-yl)phenyl]pyrimidin-2-yl]oxypiperidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)OC1=NC=C(C=N1)C1=CC=C(C=C1)N1C(COCC1)=O LQWKFZXJUBAHSR-UHFFFAOYSA-N 0.000 description 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
- 229960003352 tertatolol Drugs 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229950000584 tezosentan Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- ODKDMMTXTVCCLJ-BVSLBCMMSA-N tmc-2-a Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N3[C@@H](CC4=CC(O)=C(C(=C4C3)O)OC)C(=O)N[C@@H](CC(CO)CO)C(O)=O)=CNC2=C1 ODKDMMTXTVCCLJ-BVSLBCMMSA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
- 229950004514 torcetrapib Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 229950002223 trecadrine Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940055755 tricor Drugs 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical class OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- YNZXWQJZEDLQEG-UHFFFAOYSA-N trimazosin Chemical compound N1=C2C(OC)=C(OC)C(OC)=CC2=C(N)N=C1N1CCN(C(=O)OCC(C)(C)O)CC1 YNZXWQJZEDLQEG-UHFFFAOYSA-N 0.000 description 1
- 229960002906 trimazosin Drugs 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960002769 zofenopril Drugs 0.000 description 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to saturated heteroaryl derivatives containing heteroaryloxy nitrogen which are useful in the field of medicine.
- This compound acts as a histamine receptor H3 antagonist and is useful as a preventive or therapeutic agent for various cardiovascular, nervous, and metabolic diseases, etc.
- histamine In mammals and other organisms, histamine, a physiologically active endogenous factor, has been shown to function as a neurotransmitter and have a wide range of pharmacological activities [see, for example, Life Sciences]. (Life Science), vol. 17, 1975, p503]. Immunohistochemical studies have revealed that histaminergic (producing) cell bodies are present in the papillary nucleus of the nodule in the posterior hypothalamus, and that histamine is projected over a very wide area in the brain. And support the diverse pharmacological effects of histamine [see, for example, Journal ⁇ of'Compliance Neurology ⁇ , 273, 283].
- histaminergic nerves in the papillary nucleus of the nodule in the posterior hypothalamus is related to histamine in brain function, especially for hypothalamic functions (sleep, arousal rhythm, endocrine, eating, drinking behavior, sexual behavior, etc.) Suggests that they play an important role in the regulation of physiological functions [eg, Progress * in * Neurobiology (Prog ressin N eurobio 1 ogy), 63, 637 (200: [year], .
- Histamine 4 also exerts its pharmacological action by acting on a specific macromolecule called a receptor on the cell membrane surface or in target cells when released from producer cells, and regulates various bodily functions. ing. To date, four histamine receptors have not been found. In particular, various pharmacological and physiological studies have shown the existence of the histamine H 3 receptor as a receptor involved in central and peripheral nervous functions of histamine.
- Pharmaceutical Sciences (Trend sin Pharmaeo1ogica1Science), Vol. 8, 24: pp. (-1 986-years)], recently,-Human and rodent histamine H3 receptors Somatic genes have been identified and their presence has been revealed [eg-Molecular Pharma:? Mouth—Gini — (Molecu lar Phrmac o l ogy), Vol. 55, pp. 11-11 (1999)].
- the histamine ⁇ 3 receptor is located in the presynaptic membrane of central or peripheral neurons and functions as an autoreceptor, controlling the release of histamine and also controlling the release of other neurotransmitters.
- the histamine ⁇ 3 receptor agonist, antagonist or inverse agonist regulates release of histamine, noradrenaline, serotonin, acetylcholine or dopamine from nerve endings.
- agonists such as (R)-( ⁇ ) -methylhistamine inhibit the release of these neurotransmitters, and antagonists such as thioperamide (Thiope ramide) or inverse agonists.
- histamine H3 receptors are highly constitutively active in receptor-expressing cells, tissues or expressing cells, tissue-derived membrane fractions, and even in vivo (endogenous agonists such as histamine).
- histamine histamine
- These constitutive activities have been reported to be suppressed by inverse agonists. For example, thioperamide or ciproxyphan suppresses homeostatic receptor activity, resulting in the release of neurotransmitters from nerve endings, eg For example, histamine release and release are promoted.
- thioperamide or GT-2331 a histamine H3 receptor antagonist or inverse agonist, reduces dysarthria and sleep in narcolepsy dogs [for example, Sleep (S1eep), Volume 24, Abstracts] A23 page (2001)
- H3 receptors are involved in coordination between wakeful sleep and sleep disorders, and that selective H3 agonists or antagonists, or inverse agonists, And various disorders associated with sleep disorders (eg, idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, periodic limb movement disorder during sleep, sleep apnea syndrome group, circadian rhythm disorder, Chronic fatigue syndrome, REM sleep disorder, elderly insomnia, night shift
- insomnia idiopathic insomnia
- repetitive insomnia idiopathic insomnia
- intrinsic insomnia idiopathic insomnia
- depression idiopathic insomnia
- schizophrenia idiopathic insomnia
- Histamine is suggested to be involved in regulating eating behavior [see, for example, Brain Research, 793, 279-page (19-98) Year) see].
- Thioperamide a histamine H3 receptor antagonist or inverse agonist, suppresses eating behavior in a dose-dependent manner.
- Thioperamide also promotes the release of histamine in the brain [see, for example, Life Sciences (Life Sciences), 69, 469 (2001)].
- H3 receptor is involved in the regulation of eating behavior, and that H3 antagonists or inverse agonists are associated with metabolic pathways such as eating disorders, obesity, diabetes, leanness, and hyperlipidemia. It suggests that it may be useful for prevention or treatment of the disease.
- administration of the histamine H.3 receptor agonist (R)-(a) -methylhistamine dose-dependently reduces basal diastolic blood pressure.
- histamine H3 receptor antagonists or the inverse agonist thioperamide [see, for example, Journal of Physiology and Pharmacology (Journal of Phy siology and P). harma co 1 o gy), 49, 191 (1998)].
- histamine H3 receptors are involved in regulating blood pressure, heart rate, and cardiovascular output, and that histamine H3 receptor agonists or antagonists or inverse agonists This suggests that the drug may be useful for preventing or treating cardiovascular diseases such as hypertension and various heart diseases.
- histamine H3 receptor agonist R-() -methylhistamine
- thioperamide a histamine H3 receptor antagonist or inverse agonist
- amnesia caused by the drug in a scopolamine-induced amnesia test in a dose-dependent manner
- histamine H3 receptor antagonists or inverse agonists can be used to prevent or treat various diseases associated with memory and learning disorders, such as Alzheimer's disease, Parkinson's disease or attention deficit / hyperactivity disorder.
- histamine an antagonist of the H3 receptor or thioperamide, an inverse agonist, induced seizures induced by lightning stimuli or epileptiform seizures induced by pentylenetetrazol (PTZ). It has been shown to inhibit in a dose-dependent manner (e.g., Europian Journal of Phorma cology, Vol. 234, p. 29 (1993) and Pharmacology, biochemistry and 'beheihi / (Pharrt aco 1 ogy, Biochemistry and Behavo.r), 68, 735 (2001)].
- PTZ pentylenetetrazol
- Examples of the compound having histamine H 3 receptor antagonism or inverse agonism include, in addition to the above-mentioned thioperamide or cycloxyphan, for example, the following formula (A)
- the compound represented by the formula (A) has a propylene group between the pyrrolidinyl group and the oxygen atom, whereas the compound (I) according to the present invention has an oxygen atom and a pyrrolidinyl group.
- the group differs from the group in that they are directly bonded.
- the phenyl group is bonded to the oxygen atom, whereas the compound of the present invention has the following formula (I-11)
- the compound represented by the formula (B) has a 4-acetylphenoxy group and a pyrrolidinyl group, which are a part of the constituents of the compound according to the present invention, and the compound represented by the formula (B) has a 4-acetylphenoxy group and a pyrrolidinyl group.
- the compound represented by the formula (B) has a 4-acetylphenoxy group and a pyrrolidinyl group.
- the position of the nitrogen atom in the pyrrolidinyl group of the formula (B) is also different from the compound according to the present invention.
- the compound represented by (C) is described [for example, JP-A-2003-064081].
- the compound represented by the above formula (C) has a octahydropyrido [1,2-a] pyrazidyl group, but the compound according to the present invention has a Y moiety in the formula (I)
- a monocyclic or bicyclic group having one nitrogen atom in the ring such as a pyrrolidinyl group or an octahydroquinolidinyl group.
- the octahydropyridine [1,2-a] birazinyl group and the oxygen atom are bonded via a propylene group
- the compound according to the present invention is directly bonded without using an alkylene group.
- the structure is essentially different.
- a compound having an N_isopropyl-piperidine-4-yl group represented by the following formula is described as a compound that binds strongly and selectively to the histamine H 3 receptor [for example, see WO 03X024929]. .
- the compound represented by the formula (D) is common to the compound according to the present invention in that it has an N-isopropylpiperidine-4-yl group, but the compound represented by the formula (I)
- the compound according to the present invention does not have a biphenyl group, and in the compound represented by the formula (D), the biphenyl group and the N-isopropylpiperidine-14-yl group are a carbamoylmethyl group.
- the substituted piperidinyl group of the formula (I) is bonded to the above-mentioned formula (1-1) via an oxygen atom.
- the compound represented by (E) is described [for example, WO01 / 19817].
- the position of N in homopiperidine is determined according to the present invention. It differs from the N position of the compound.
- the compound represented by the above formula (E) has a property as a dicotin acetylcholine receptor ligand, whereas the compound according to the present invention has a histamine H3 receptor antagonist or It has the properties of an inverse agonist.
- WO 01 Z 198 17 does not disclose that the compound represented by the formula (E) acts as a histamine H 3 receptor antagonist or an inverse agonist. There is no description suggesting.
- the compound represented by the above formula (F) is structurally different from the compound according to the present invention in having a methyl group at the 3- and 6-positions of the pyrazine ring in the formula (F).
- the use of this compound is as a CRF receptor ligand, and the above WO 01/80608 publication does not describe a histamine H3 receptor antagonist or inverse agonist. There is no description suggesting these.
- the present invention provides a heteroaryloxy nitrogen-containing saturated heterocyclic derivative having an activity of antagonizing the binding of histamine to the histamine H3 receptor or an activity of suppressing the homeostatic activity of the histamine H3 receptor, Metabolic diseases such as hypertension, diabetes, hormonal secretion, hyperlipidemia, gout, fatty liver, etc.
- angina pectoris acute, congestive heart failure, myocardial infarction, atherosclerosis, hypertension , Kidney disease, sleep disorders and various disorders accompanied by sleep disorders, such as idiopathic hypersomnia, repetitive hypersomnia, intrinsic hypersomnia, narcolepsy, sleep periodic limb movement disorder, sleep apnea syndrome, Cardiovascular disorders such as daily rhythm disorders, chronic fatigue syndrome, REM sleep disorders, insomnia for the elderly, sleep insanity for night-shift workers, idiopathic insomnia, repetitive insomnia, intrinsic insomnia, electrolyte abnormalities, etc.
- Illnesses such as binge eating, emotional disorders, depression, anxiety, epilepsy, delirium, dementia, schizophrenia, Attention deficitHyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, cognitive disorder, movement disorder, paresthesia, olfactory disorder, epilepsy, morphine tolerance, drug addiction, alcohol dependence, etc. It is intended to provide a prophylactic or therapeutic agent for peripheral nervous system diseases.
- the present inventors have conducted intensive studies to develop a compound that inhibits the binding of histamine to the histamine H3 receptor, and the compound according to the present invention is a histamine H3 receptor antagonist and Z or an inverse agonist.
- a heteroaryloxycycloalkylamine derivative characterized by having an action is a novel substance not described in the literature, and a specific compound containing the compound is effective as a histamine H3 receptor antagonist or inverse agonist.
- the present inventors have found that the present invention has been completed based on such findings.
- X i, X 2 or X 3 each independently represent N or CH (however, not all of X i, X 2 and X 3 may be CH at the same time); (II)
- R is a cyano group, a hydroxy group, a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group)),
- a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a lower alkylsulfonyl group, a cyclo-lower alkylsulfonyl group, a halogen atom, a mono-lower alkylaminocarbonyloxy group, a di-lower alkylaminocarbonyl Oxy group, mono-lower alkylcarbamo Linear or branched lower alkyl, which may be substituted with a group selected from the group consisting of benzyl group, di-lower alkyl group rubamoyl group, rubamoyl group, cycloalkyliminocarbonyl group and trifluoromethyl group.
- R o represents a lower alkyl group having 1 to 4 carbon atoms, and represents a cyano group, a hydroxy group, or a lower alkyl group (the lower alkyl group is a hydroxy group, a halogen group, Atom or amino group), lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), lower alkylsulfonyl group, cyclo-lower alkylsulfonyl group, halogen atom Mono-lower alkyl rubamoyl group, di-lower alkyl rubamoyl group, rubamoyl group, cycloalkyliminocarbamoyl group, lactam ring, trifluoromethyl group, mono-lower alkylamino group, di-lower alkylamino group, alkanoyl group, An alkoxycarbonylamino group (a nitrogen atom in the group may be substituted with a lower alkyl group), an alk
- R 1 and R 2 are the same or different and each represents a lower alkyl group or a mono- or di-lower alkyl group rubamoyl group, or R i and R 2 are taken together with an adjacent nitrogen atom.
- each symbol is the same as defined above, is a C! -4 lower alkylene group, a carbonyl group, — C (0) 101, one C 1.4 lower alkylene one C (0 ) One, one C 1-4 lower alkylene one C ( ⁇ ) one, -C! -4 lower alkylene — C ( ⁇ ) one N
- Q 1 is a cyano group, a hydroxy group, a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group), a lower alkoxy group (the A lower alkoxy group may be substituted with a halogen atom), a lower alkylsulfonyl group, a cycloalkyl lower alkylsulfonyl group, an octogen atom, a mono-lower alkylaminocarbonyloxy group, a di-lower alkylaminocarbonyloxy group, Mono-lower alkyl rubamoyl group, di-lower alkyl rubamoyl group, rubamoyl group, cycloalky
- R 10 and R 20 are combined with a nitrogen atom adjacent to each other to form a 3 to 9-membered lactam ring, a heterocyclic ring having 3 to 8 carbon atoms (R 10 and R 20 May have, in addition to the nitrogen atom adjacent to each other, one or two nitrogen atoms or oxygen atoms in the ring as a constituent atom of the heterocyclic group), and one to four nitrogen atoms in the ring.
- one Y is a hydroxy group, a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group), a lower alkoxy group (the lower alkoxy group)
- one Y is a hydroxy group, a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group), a lower alkoxy group (the lower alkoxy group) Group may be substituted with a halogen atom), lower alkylsulfonyl group, cycloalkyl lower alkylsulfonyl group, halogen atom, mono-lower alkylaminoaminopropyl group, di-lower alkylaminocarbonyloxy group, mono-lower alkyl Carbamoyl group, di-lower alkyl rubamoyl group, cycloalkyliminocarbamoyl group, lactam ring, mono-lower-alkylamino group, di-lower-alkylamino group, alkanoyl group, alkoxyl-propionylamino group (the nitrogen atom in the group is lower al
- one Y is a hydroxy group, a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group), a lower alkoxy group (the lower alkoxy group)
- a furyl group which may have 1 to 2, a furyl group, a chenyl group, a pyrrolyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, a thiadiazolyl group, an isothiazolyl group, an oxazolyl group, a isoxazolyl group, a pyridyl group, a pyridazinyl group, a pyrimidinyl group, or A compound according to the above (1), which is a pyrazinyl group, or a pharmaceutically acceptable salt thereof;
- -Y is a hydroxy group, a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group), a lower alkoxy group (the lower alkoxy group)
- the group may be substituted with a halogen atom), a halogen atom, a mono-lower alkylamino carbonyl group, a di-lower alkylaminocarbonyloxy group, a mono-lower alkyl rubamoyl group, a di-lower alkyl rubamoyl group, cyclo Alkylimino carbamoyl group, lactam ring, mono-lower alkylamino group, di-lower alkylamino group, alkanoyl group, alkoxycarbonylamino group (the nitrogen atom in the group may be substituted with a lower alkyl group), alkano Ilamino group (The nitrogen atom in the group may be substituted with
- a compound according to the above (1) which is an oxesynyl group, a tetrahydrofuranyl group, a tetrahydrovinylil group, a pyrrolidinyl group, a piperidinyl group, a homopiperidinyl group, a morpholinyl group, a homomorpholinyl group, or a pharmaceutically acceptable compound thereof. salt,
- the compound represented by the formula (I) is 2- (1-cyclopentylpiberidin-4-yloxy) -5- (4-cyanophenyl) pyrimidine, 2- (1-sopropylpiperidine-1-4-yloxy) )-5-(4-Cyanophenyl) pyrimidine, 2- (1-cyclopentylpyrrolidine-3-yloxy)-5--(4 -l-rubamoylphenyl) pyrimidine, 2--(1-Cyclopentylpyrrolidine-1 -3-yloxy)- 5- (4-Cyanophenyl) pyrimidine, 2-1 (1-cyclopentylpiperidine-1-4-yloxy)-5- ⁇ (3-Methyl-1 2,4,1-oxodiazol-5-yl) phenyl ⁇ Pyrimidine, 2 -(1-cyclopentylpyridine-1 4-yloxy)-5-(4-cyanophenyl) pyridine, 2 (1-cyclopen
- a histamine receptor H3 antagonist or inverse agonist comprising a compound according to any of the above formulas (1) to (12) as an active ingredient;
- a histamine receptor H3 antagonist comprising the compound according to any one of the formulas (1) to (12) as an active ingredient
- a histamine receptor Yuichi H3 inverse agonist comprising a compound according to any of the above formulas (1) to (12) as an active ingredient;
- a metabolic disease such as obesity, diabetes, abnormal hormonal secretion, hyperlipidemia, gout, and fatty liver, comprising a compound according to any one of the formulas (1) to (7) as an active ingredient.
- R 1 is a cyano group, a hydroxy group, or a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom, or an amino group)
- a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a halogen atom, a mono-lower alkylaminocarbonyloxy group, a di-lower alkylaminocarbonyloxy group, a mono-lower alkylcarbamoyl group, A straight-chain or branched lower alkyl group which may be substituted with a group selected from the group consisting of lower alkyl groups such as rubamoyl group, rubamoyl group, cycloalkyliminocarbonyl group, and trifluoromethyl group; Group), C3-C9 alkyl group, aralkyl group or C3-C8 A telocyclic group
- L 1 represents a lower alkylene group having 1 to 4 carbon atoms or a single bond
- M represents an oxygen atom or a formula (V)
- Q 1 represents a cyano group, a hydroxy group, or a lower alkyl group (the lower alkyl group is a hydroxy group, a halogen group, Atom or an amino group), a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a lower alkylsulfonyl group, a cyclo-lower alkylsulfonyl group, a halogen atom, Mono-lower-alkylaminocarbonyloxy group, di-lower-alkylaminocarbonyloxy group, mono-lower-alkyl rubamoyl group, di-lower-alkyl rubamoyl group, dylvamoyl group, cycloalkyliminocarbamoyl group, lactam ring, trifluoromethyl group, Mono-lower alkylamino group, di-low
- a branched lower alkyl group a cycloalkyl group having 3 to 9 carbon atoms, a phenyl group, a 5 to 6-membered heteroaryl group, a heterocyclic group having 3 to 8 carbon atoms (a nitrogen atom or Having one or two oxygen atoms), a naphthyl group or a condensed heteroaryl group, or If necessary, a group corresponding to Q 1 in which a protecting group has been introduced, or a group represented by the formula (V-11)
- R 1 and R 2 are the same or different and each represents a lower alkyl group or a mono- or di-lower alkyl group rubamoyl group, or R 1 and R 2 together with an adjacent nitrogen atom A 3- to 9-membered lactam ring, a heterocyclic group having 3 to 8 carbon atoms (having one or two nitrogen or oxygen atoms in the heterocyclic group), a 5-membered heteroaryl group or Or a condensed heteroaryl group) or a group corresponding to -Y in which a protecting group is introduced, if necessary, into a substituent of 1Y.
- VIII a compound represented by the general formula (VIII)
- Wi is the following formula (I 1— 1)
- R 1 represents a cyano group, a hydroxy group, or a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom, or an amino group)
- a lower alkoxy group (the lower alkoxy group may be substituted with an octane atom), a halogen atom, a mono-lower alkylamino group Substituted with a group selected from the group consisting of a luponyloxy group, a di-lower alkylaminocarbonyloxy group, a mono-lower alkylcarbamoyl group, a di-lower alkyl group, a rubamoyl group, a dirubamoyl group, a cycloalkylimino group, and a trifluoromethyl group.
- a straight-chain or branched lower alkyl group (excluding a methyl group), a cycloalkyl group having 3 to 9 carbon atoms, an aralkyl group or a heterocyclic group having 3 to 8 carbon atoms, which may be A nitrogen atom or an oxygen atom in the ring group) or a group in which a protecting group is appropriately introduced into the substituent of R, or
- Q i represents a cyano group, a hydroxy group, a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group), a lower alkoxy group (a narrow lower alkoxy group) May be substituted with a halogen atom), a lower alkylsulfonyl group, a cyclo-lower alkylsulfonyl group, a halogen atom, a mono-lower alkylaminoaminocarbonyl group, a di-lower alkylaminocarbonyloxy group, a mono-lower alkyl group Rubamoyl group, di-lower alkyl group lubamoyl group, di-rubamoyl group, cycloalkyliminocarbamoyl group, lactam ring, trifluoromethyl group, mono-lower alkylamino group, di-lower alkylamino group, alkan
- a lower alkyl group May be substituted with a lower alkyl group), which may be substituted with a group selected from the group consisting of: a straight-chain or branched lower alkyl group, a cycloalkyl group having 3 to 9 carbon atoms, To a phenyl group, a 5- to 6-membered heteroaryl group, a C3-C8 heterocyclic group (having one or two nitrogen or oxygen atoms in the heterocyclic group), a naphthyl group or a condensed ring If necessary, a group corresponding to Q 1 in which a protecting group has been introduced, or a group represented by the formula (V-1)
- [ ⁇ ⁇ , 2 or 3 each independently represent ⁇ or CH (however, X i,
- L 1 represents a lower alkylene group having 1 to 4 carbon atoms or a single bond
- M represents an oxygen atom or a formula (V)
- R 0 represents a lower alkyl group having 1 to 4 carbon atoms
- Q 1 represents a cyano group, a hydroxy group, or a lower alkyl group
- the lower alkyl group is a hydroxy group
- a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a lower alkylsulfonyl group, a cyclo-lower alkylsulfonyl group, Halogen atom, mono-lower alkylaminoaminocarpoxyloxy group, di-lower alkylaminocarboxyloxyl group, mono-lower alkyl alkyl group, di-lower alkyl carpamoyl group, alkyl group, cycloalkyl iminocarbamoyl group, lactam ring, tri Fluoromethyl group, mono-lower alkylamino group, di-lower alkylamino group, al A noyl group, an alkoxy
- branched lower alkyl group carbon A cycloalkyl group of the formulas 3 to 9, a phenyl group, a 5- or 6-membered heterocyclic group, a heterocyclic group having a carbon number of 3 to 8 (in the heterocyclic group, a nitrogen atom or an oxygen atom is 1 or 2 ), A naphthyl group or a condensed heteroaryl group, or a group corresponding to Q 1 in which a protecting group has been introduced, if necessary, or a compound represented by the formula (V-1)
- R 1 and R 2 are the same or different and each represents a lower alkyl group or a lower alkyl group rubamoyl group having 1 to 6 carbon atoms, or R 1 and R 2 together with an adjacent nitrogen atom
- a 5-membered heteroaryl L represents a group or a condensed heteroaryl group) or a group corresponding to 1 Y in which a protecting group has been introduced, if necessary, for a substituent of -Y. 2 represents a leaving group.
- XV a compound represented by the general formula (XV)
- the “aryl group” includes, for example, a hydrocarbon ring aryl group having 6 to 14 carbon atoms such as a phenyl group, a naphthyl group, a biphenyl group, an anthryl group and the like.
- lower alkyl group means a linear or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and sec_butyl.
- alkylene group means a linear or branched alkylene group having 1 to 6 carbon atoms, and examples thereof include a methylene group, an ethylene group, a trimethylene group, a tetramethylene group, and a pentamethylene group.
- cycloalkyl group having 3 to 9 carbon atoms includes, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, and a cyclononyl group.
- Alkoxy group means a group in which a hydrogen atom of a hydroxy group is substituted by the above-mentioned lower alkyl group. Examples thereof include a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, a sec-butoxy group and a tert- Butoxy group, pentyloxy group, isopentyloxy group, hexyloxy group, and isohexyloxy group.
- alkylsulfonyl group means a group in which the alkyl group and the sulfonyl group are bonded, and examples thereof include a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, an isopropylsulfonyl group, and a butylsulfonyl group.
- Alkylsulfonylamino group means a group in which one of the hydrogen atoms of the amino group is substituted with the above-mentioned alkylsulfonyl group, for example, methylsulfonylamino group, ethylsulfonylamino group, propylsulfonylamino Amino group, isopropylsulfonylamino group, butylsulfonylamino group, sec—butylsulfonylamino group, tert—butylsulfonylamino group, N-methyl-methylsulfonylamino group, N-methylethylsulfonylamino group, N-methyl-propylsulfonylamino group, N-methyl-isopropylsulfonylamino group, N-methyl-butylsulfonylamino group, N-methyl-sec-butyls
- cyclo lower alkylsulfonyl group means a group in which the above “cycloalkyl group having 3 to 9 carbon atoms” ′ and a sulfonyl group are bonded, for example, a cyclopropylsulfonyl group, a cyclobutylsulfonyl group, a cyclopentylsulfonyl group And cyclohexylsulfonyl, cycloheptylsulfonyl, cyclooctylsulfonyl, and cyclononylsulfonyl.
- Alkyl group means the lower alkyl group having the aryl group, for example, benzyl group, 1-1phenylethyl group, 2-phenylethyl group, 1-naphthylmethyl group, 21-naphthylmethyl group, etc. Is mentioned.
- Heteroaryl group means a 5- to 7-membered monocyclic ring having 1 to 3 hetero atoms selected from the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom, or Means a bicyclic heteroaryl group in which a heteroaryl group and a benzene ring or a pyridine ring are condensed.
- Halogen atom means, for example, a fluorine atom, a chlorine atom, a bromine atom, an iodine atom and the like.
- alkoxyl ponylamino group means a group in which one of the hydrogen atoms of the amino group is substituted with the above-mentioned alkoxycarbonyl group. Isopropoxyl-ponylamino group, butoxycarpylamino group, sec-butoxyl-ponylamino group, tert-butoxyl-ponylamino group, pentyloxycarbonylamino group, (N-methyl) methoxycarbonylamino group, (N-methyl) X 2
- Toxicarbonylamino group (N-methyl) propoxyl-ponylamino group, (N-methyl) isopropoxycarbonylamino group, (N-methyl) butoxycarbonylamino group, (N-methyl) secbutoxycarbonylamino group , (N-methyl) tert-butoxyl ponylamino group, (N-ethyl) methoxycarbonylamino group, (N-ethyl) ethoxycarbonylamino group, (N-ethyl) propoxyl ponylamino group, (N-ethyl) iso A propoxycarbonylamino group, a (N-ethyl) butoxycarponylamino group, a (N-ethyl) sec-butoxylaminolamino group, and a (N-ethyl) tert-butoxycarbonylamino group.
- Hydroalkyl group means a group in which one of the hydrogen atoms in the lower alkyl group is substituted with a hydroxy group, such as a hydroxymethyl group, a hydroxyethyl group, a 1-hydroxypropyl group, and a 1-hydroxyethyl group. Examples thereof include a tyl group, a 2-hydroxypropyl group, and a 2-hydroxy-1-methylethyl group.
- the “mono-lower alkylcarbamoyl group” means a carbamoyl group mono-substituted with the lower alkyl group, for example, a methylcarbamoyl group, an ethylcarbamoyl group, a propyl-l-bamoyl group, an isopropyl-l-l-bamoyl group, and a butyl-l-carbamoyl group. , Sec-butyl carbamoyl group, tert-butyl carbamoyl group and the like.
- di-lower alkyl group rubamoyl group means a rubamoyl group di-substituted with the same or different lower alkyl group.
- examples of the “di-lower alkyl group rubamoyl group” include dimethylcarbamoyl group and Examples thereof include a rucarbamoyl group, an ethylmethylcarbamoyl group, a dipropylcarbamoyl group, a methylpropyl-based rubamoyl group, and a disopropyl-based rubamoyl group.
- a nitrogen atom constituting the group and a same or different lower alkyl group bonded to the nitrogen atom are combined to form a 5- to 8-membered monocyclic ring.
- a case where the monocyclic ring and a benzene ring or pyr are condensed to form a bicyclic ring are condensed to form a bicyclic ring.
- Alkylamino group means an amino group mono-substituted by the lower alkyl group, for example, methylamino group, ethylamino group, propylamino group, isopropylamino group, butylamino group, sec-butylamino group or tert-butylamino group. And a lumino group.
- Dialkylamino group means an amino group di-substituted by the same or different lower alkyl group, for example, dimethylamino group, ethylamino group, dibutylamino group, methylpropylamino group or diisopropylamino group. And the like.
- Aminoalkyl group means a group in which one of the hydrogen atoms constituting the above-mentioned alkyl group is substituted with an amino group, and examples thereof include an aminomethyl group, an aminoethyl group and an aminopropyl group.
- alkanoyl group means a group in which the above-mentioned alkyl group and carbonyl group are bonded, and examples thereof include a methylcarbonyl group, an ethylcarbonyl group, a propylcarbonyl group, and an isopropyl group.
- alkanoylamino group means a group in which the above-mentioned alkanoyl group and amino group are bonded, such as acetylamino, propanoylamino, butanoylamino, pentanoylamino, N-methylamino.
- Cetylamino group, N-methylpropanoylamino group, N-methyl-butanoylamino group, N-methyl-pentano Examples include an ilamino group, an N-ethyl-acetylamino group, an N-ethylloopanoylamino group, an N-ethyllooptanylamino group, and an N-ethylethylpentanoylamino group.
- mono-lower alkylamino propyloxy group refers to a monoalkyl-substituted oxypropyl group such as a methylamino carboxy group, an ethylamino carboxy group, and a propyl group.
- Examples include an aminocarbonyloxy group and an isopropylaminocarbonyloxy group.
- di-lower alkylaminocarboxy group means a di-substituted alkoxy group di-substituted with the above-mentioned lower alkyl group, for example, dimethylamino-aminopropyl group, dimethylaminocarbonyl group, diethylaminocarbonyl group, di-amino group. Examples thereof include a isopropylaminocarbonyloxy group and an ethylmethylaminocarbonyloxy group.
- XI, 2 or 3 each independently represents nitrogen atom or CH and (although, X i, all X 2 and X 3 do not become CH simultaneously) compounds you express in Is shown.
- M in the formula (II) represents an integer of 0 to 3.
- R represents a cyano group, a hydroxy group, a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group), a lower alkoxy group (the lower alkoxy group May be substituted with a halogen atom), a halogen atom, a mono-lower alkylaminocarbonyloxy group, a di-lower alkylaminocarbonyloxy group, a mono-lower alkyl force rubamoyl group, a di-lower alkyl force rubamoyl group, a force rubamoyl A linear or linear group, which may be substituted with a group selected from the group consisting of a cycloalkylimino propyl group and a trifluoromethyl group.
- ⁇ Is a branched lower alkyl group (excluding a methyl group), a C 3-9 cycloalkyl group, an aralkyl group or a C 3-8 heterocyclic group (in which a nitrogen atom or oxygen Has 1 or 2 atoms).
- the “linear or branched lower alkyl group” represented by R in the formula (II) has the same meaning as the above-defined lower alkyl group (excluding the methyl group), for example, ethyl group, propyl group, butyl Group, isopropyl group, isobutyl group, tert-butyl group pentyl group, isoamyl group, neopentyl group, 1,1-dimethylpropyl group, 1-methylbutyl group, 2-methylbutyl group, hexyl group, isohexyl group, 1 And a methylpentyl group and a 1,1-dimethylbutyl group.
- the substituent which the lower alkyl group may have is, among the substituents described above, a cyano group, a hydroxy group, a lower alkoxy group, Groups (the lower alkoxy group may be substituted with a halogen atom), a halogen atom, a di-lower alkylaminocarbonyloxy group, a di-lower alkyl group rubamoyl group, and a trifluoromethyl group, and a hydroxy group And a lower alkoxy group (the lower alkoxy group may be substituted with an octogen atom) or a trifluoromethyl group.
- the "lower alkyl group substituted with a cyano group" represented by R includes, for example, 1-cyanoethyl group, 2-cyanoethyl group, 2-cyano-1,1,1-dimethylethyl group, and 5-cyanopentyl group , 4-cyanopentyl group, 3-cyanopentyl group, 2-cyanopentyl group, 2-cyanopentyl group, 1-cyanopentyl group, 3-cyano 1-methylpropyl group, 2-cyano_1-methylethyl group, 1-cyanomethylpropyl And the like.
- lower alkyl group substituted with a hydroxy group for R, more specifically, for example, 1-hydroxyethyl group, 2-hydroxyethyl group, 1-hydroxypropyl group, 2-hydroxypropyl group, 5-hydroxypentyl group, 4-hydroxypentyl group, 3-hydroxypentyl group, 2-hydroxypentyl group, 1-hydroxypentyl group, 1-hydroxyethyl group, 2-hydroxyethyl group, 2-hydroxy-11 Examples include a methylethyl group, a 2-hydroxy-1-methylethyl group, a 3-hydroxy-1-methylpropyl group, a 1-hydroxymethylpropyl group, and a 1,1-dimethyl-2-hydroxyethyl group.
- R As the “lower alkyl group substituted by an alkoxy group (the alkoxy group may be substituted by a halogen atom)” represented by R, more specifically, for example, 2 1- (2-chloroethoxy) ethyl group, 2- (chloromethoxy) ethyl group, 1-methoxethyl group, 2-methoxyethyl group, 2-methoxy-1-methylethyl group, 1-chloromethoxy-1-methylethyl group, 3 —Methoxy-1-methylpropyl, 1- (methoxymethyl) propyl, 3- (chloromethoxy) 1-1-methylpropyl, 1- (chloromethoxymethyl) propyl, 1,1-dimethyl-2-methoxyethyl, 2 — (Chloromethoxy)-a 1,1-dimethylethyl group, a 5-methoxypentyl group, a 4-methoxypentyl group, a 3-methoxyp
- the “lower alkyl group substituted by a halogen atom” represented by R includes, for example, 1-fluoroethyl group, 2-fluoroethyl group, 2-fluoro-1-methylethyl group, 31-fluoro-1-methyl methyl group Pyr group, 2,2-difluoroethyl group, 2,2,2-Trifluoroethyl group, 1-Fluoromethyl group Pill group, 3,3-Difluoropropyl group, 3,3,3-Trifluor O-propyl, 2-fluoro-1,1-dimethylethyl, 1-chloroethyl, 2-chloroethyl, 2-chloro-1-methylethyl, 3-chloro-1-methylpropyl, 1-chloro Examples include a methylpropyl group and a 2-chloro-1,1-dimethylethyl group.
- Examples of the “lower alkyl group substituted by a mono-lower alkylaminocarbonyloxy group” represented by R include 2- (ethylaminopropyloxy) ethyl group, 2- (pyruaminocarbonyloxy) ethyl group, (Isopropylaminocarboxy) ethyl group and the like.
- Examples of the “lower alkyl group substituted by a dialkylaminocarponyloxy group” represented by R include, for example, an 11- (dimethylaminoaminopropyl) ethyl group, a 2- (dimethylaminoaminopropyl) ethyl group, — (Getylaminocarbonyloxy) ethyl group, 2— (Getylaminocarbonyloxy) ethyl group, 1- (Diisopropylaminocarbonyloxy) ethyl group, 2- (Dimethylaminocarbonyloxy) -1- 1-methylethyl And 2- (diethylaminocarbonyloxy) -11-methylethyl group and the like.
- Examples of the “lower alkyl group substituted with a dialkyl rubamoyl group” represented by R include, for example, a 2- (methylcarbamoyl) ethyl group and an 11- (methyl rubamoyl) ethyl group.
- Examples of the “lower alkyl group substituted with a sorbamoyl group” represented by R include, more specifically, 2- 2- rubamoyl ethyl group, 3- 3- rubamoyl propyl group, 2- 2- rubamoyl-1-methylethyl group and the like. No.
- the “lower alkyl group substituted by a trifluoromethyl group” represented by R is, for example, a 3,3,3-trifluoropropyl group, a 2,2,2-trifluoro-1 Examples include a monomethylethyl group, a 4,4,4-trifluorobutyl group, and a 3,3,3-trifluoro-1-methylpropyl group.
- Examples of the “lower alkyl group substituted by a lower alkylsulfonyl group” represented by R include, more specifically, for example, a 2-methanesulfonylethyl group, a 1-methanesulfonylethyl group, a 2-ethanesulfonylethyl group, 2-methanesulfonyl-1-methylethyl group and the like.
- lower alkyl group substituted by a cycloalkyl lower alkylsulfonyl group represented by R, more specifically, for example, a 2-cyclopropanesulfonylethyl group, a 1-cyclopropanesulfonylethyl group, a 3-cyclobutane Examples thereof include a sulfonylpropyl group and a 2-cyclobutanesulfonylpropyl group.
- R is “a cycloalkyl group having 3 to 9 carbon atoms”
- the “cycloalkyl group having 3 to 9 carbon atoms” represented by R in the formula (II) has the same meaning as the above definition, and examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cyclohexyl group. Examples thereof include a butyl group, a cyclooctyl group, and the like.
- a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group are preferable, and a cyclopropyl group, a cyclobutyl group, and a cyclopentyl group are more preferable.
- C3-C9 cycloalkyl group when the C3-C9 cycloalkyl group may have a substituent, among the substituents described above, a cyano group A hydroxy group, a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a lower alkyl group (the lower alkoxy group is A halogen atom, a halogen atom, a di-lower alkylaminocarbonyloxy group, a di-lower alkylcarbamoyl group or a trifluoromethyl group, preferably a cyano group, a hydroxy group, a lower alkoxy group (the lower The alkoxy group may be substituted with a halogen atom), and a halogen atom or a trifluoromethyl group is more preferable.
- the cycloalkyl group having 3 to 9 carbon atoms may have the same or different 1 or 2 at the position where these substituents can be bonded.
- cycloalkyl group substituted with a lower alkyl group represented by R, more specifically, for example, 1-methylcyclopropyl group, 1-ethylcyclopropyl group, 1-methylcyclobutyl group, 1-methylcyclopentyl group, 1-methylcyclopentyl group, 1-methylcyclohexyl group, 1-ethylcyclohexyl group, 1-methylcycloheptyl group, 1-ethylcycloheptyl group, 1-methylcyclopentyl group Examples thereof include a methylcyclooctyl group and a 1-ethylcyclooctyl group.
- the “cycloalkyl group substituted by a cyano group” represented by R includes, for example, a 2-cyanocyclopropyl group, a 3-cyanocyclobutyl group, a 2-cyanocyclobutyl group, —Cyanocyclopentyl group, 3-cyanocyclopentyl group, 2-cyanocyclohexyl group, 3-cyanocyclohexyl group, 4-cyanocyclohexyl group, 2-cyanocycloheptyl group, 3-cyanocycloheptyl group, 4 —Cyanocyclyl heptyl group, 2-cyanocyclooctyl group, 3-cyanocyclooctyl group, 4-cyanocyclooctyl group, 5-cyanocyclooctyl group and the like.
- cycloalkyl group substituted with a hydroxy group represented by R includes, for example, 2-hydroxycyclopropyl, 3-hydroxycyclobutyl, 2-hydroxycyclobutyl, 2-hydroxy Cyclopentyl, 3-hydroxycyclopentyl, 2-hydroxycyclohexyl, 3-hydroxycyclohexyl, 4-hydroxycyclohexyl, 2-hydroxycyclo, 2-hydroxycyclooctyl, 3-hydroxy Cyclooctyl group, 41
- cycloalkyl group substituted by an alkoxy group (the alkoxy group may be substituted with a halogen atom)” represented by R, more specifically, for example, a 2-chloromethoxycyclopropyl group, 2 —Methoxycyclopropyl group, 2-ethoxycyclopropyl group, 2- (chloromethoxy) cyclobutyl group, 3-methoxycyclobutyl group, 2- (chloromethoxy) cyclopentyl group, 2-methoxycyclopentyl group, 3-methoxycyclopentyl group, 2- (chloromethoxy) cyclo mouth hexyl group, 2-methoxycyclohexyl group, 3-methoxycyclohexyl group,
- cycloalkyl group substituted by a halogen atom represented by R, more specifically, for example, a 2-fluorocyclopropyl group, a 3-fluorocyclobutyl group, a 2-fluorocyclobutyl group Group, 2-fluorocyclopentyl group, 3-fluorocyclopentyl group, 2-fluorocyclohexyl group, 3-fluorocyclohexyl group, 4-fluorocyclohexyl group, 2-fluorocycloheptyl group, 3-fluorocycloheptyl Group, 4-fluorocycloheptyl group, 2-fluorocyclooctyl group, 3-fluorocyclooctyl group, 4-fluorocyclooctyl group, 5-fluorocyclooctyl group, 2-chlorocyclopropyl group , 3-chlorocyclobutyl, 2-chlorocyclobutyl, 2-chlorocyclopent
- cycloalkyl group substituted by a mono-lower alkylaminocarboxy group represented by R, more specifically, for example, 2- (methylcarbamoyloxy) cyclopropyl group, 3— (methylcarbamoyloxy) Xy) cyclobutyl group, 2 1- (Methylcarbamoyloxy) cyclobutyl group, 2- (methylcarbamoyloxy) cyclopentyl group, 3- (methylcarbamoyloxy) cyclopentyl group, 2- (methylcarbamoyloxy) cyclohexyl group, 3- (methylcarbamoyloxy) cyclopentyl group (Moyloxy) cyclohexyl group, 4- (methylcarbamoyloxy) cyclohexyl group, 2- (methylcarbamoyloxy) cycloheptyl group, 3- (methylcarbamoyloxy) cycloheptyl group
- Examples of the “cycloalkyl group substituted with a di-lower alkylaminocarbonyloxy group” represented by R include, for example, 2- (dimethylcarbamoyloxy) cyclopropyl group and 3- (dimethylcarbamoyloxy) cyclopropyl group.
- cycloalkyl group substituted with a dialkyl rubamoyl group represented by R, more specifically, for example, 2- (dimethylcarbamoyl) cyclopropyl group, 31- (dimethylcarbamoyl) cyclobutyl group, 2- (dimethyl Carbamoyl) cyclobutyl group, 2- (dimethylcarbamoyl) cyclopentyl group, 3- (dimethylcarbamoyl) cyclopentyl group, 2- (dimethylcarbamoyl) cyclohexyl group, 31- (dimethylcarbamoyl) cyclohexyl group, 4- (dimethylcarboxyl) Rubamoyl) cyclohexyl group, 2- (dimethylcarbamoyl) cycloheptyl group, 3- (dimethylcarbamoyl) cycloheptyl group,-(dimethylcarbamoyl group
- the “cycloalkyl group substituted with an alkylcarbamoyl group” represented by R includes 21- (methylcarbamoyl) cyclopropyl, 31- (methylcarbamoyl) cyclobutyl, and 21-methylcarbamoyl ) Cyclobutyl group, 2- (methylcarbamoyl) cyclopentyl group, 3- (methylcarbamoyl) cyclopentyl group, 2- (methylcarbamoyl) cyclohexyl group, 3- (methylcarbamoyl) cyclohexyl group, 4- (methyl (Carbamoyl) cyclohexyl group, 2- (methylcarbamoyl) cycloheptyl group, 31- (methylcarbamoyl) cycloheptyl group, 41- (methylcarbamoyl) cycloheptyl group, 21- (methylcarbamoyl) cyclooct
- the “cycloalkyl group substituted with a l-rubamoyl group” represented by R includes, for example, 2 lrubamoylcyclopropyl group, 3 lrubamoylcyclobutyl group, 2 lrubamoylcyclobutyl group Group, 2 rubamoyl cyclopentyl group, 3 rubamoyl cyclopentyl group, 2 rubamoyl cyclohexyl group, 3 rubamoyl cyclohexyl group, 4 rubamoyl cyclohexyl group, 2 lbamoyl cycloheptyl group Group, 3 rubamoyl cycloheptyl group, 4 carbamoyl cycloheptyl group, 2 lbamoyl cyclooctyl group, 3 lbamoyl cyclooctyl group, 4 rubamoyl cyclooctyl group, 5 And
- cycloalkyl group substituted by a trifluoromethyl group represented by R, more specifically, for example, a 2- (trifluoromethyl) cyclopropyl group, a 2- (trifluoromethyl) cyclobutyl group , 3-1- (trifluoromethyl) cyclobut Tyl group, 2- (trifluoromethyl) cyclopentyl group, 3- (trifluoromethyl) cyclopentyl group, 2- (trifluoromethyl) cyclohexyl group, 3- (trifluoromethyl) cyclohexyl group, 4 — (Trifluoromethyl) cyclohexyl group, 2— (trifluoromethyl) cycloheptyl group, 3— (trifluoromethyl) cycloheptyl group, 41- (trifluoromethyl) cycloheptyl group, 2 — (Trifluoromethyl) cyclooctyl group, 3- (trifluoromethyl) cyclomethyl
- Examples of the “lower alkylsulfonyl-substituted cycloalkyl group” represented by R include, for example, 2-methanesulfonylcyclopropyl group, 2-methanesulfonylcyclobutyl group, 3-methanesulfonylcyclobutyl group Group, 2-methanesulfonylcyclopentyl group, 3-methanesulfonylcyclopentyl group, 2-methanesulfonylcyclohexyl group, 3-methanesulfonylcyclohexyl group, 4-methanesulfonylcyclohexyl group, 2-methanesulfonyl group Rucycloheptyl group, 3-methanesulfonylcycloheptyl group, 4-methansulfonylcycloheptyl group, 2-methanesulfonylcyclooctyl group, 31-me
- the “cyclo lower alkylsulfonyl-substituted cycloalkyl group” represented by R is, for example, 2-cyclopropanesulfonylcyclopropyl group, 2-cyclopropanesulfonylcyclobutyl group, 3 —Cyclopropanesulfonylcyclobutyl group, 2-cyclopropanesulfonylcyclopentyl group, 3-cyclopropanesulfonylcyclopentyl group, 2-cyclopropanesulfonylcyclohexyl group, 3-cyclopropanesulfonylcyclohexyl group, 4-cyclopropanesulfonylcyclohexyl group, 2-cyclopropanesulfonylcycloheptyl group, 3-cyclopropanesulfonylcycloheptyl group, 4-cyclopropanesulfonylcycloheptyl group, 2-cyclopropanesulfonyl
- the “aralkyl group” represented by R in the formula (II) refers to the lower alkyl group having a hydrocarbon ring aryl group having 6 to 14 carbon atoms such as a phenyl group, a naphthyl group and a biphenyl group. It means, for example, benzyl group, 2-phenylethyl group, 1-phenylethyl group, 1-naphthylmethyl group, 2-naphthylmethyl group, 1-naphthalene-1-ethyl group, and 1-naphthalene-12-ylethyl group.
- a benzyl group, a 2-phenylethyl group, a 1-phenylethyl group, a 1-naphthylmethyl group or a 2-naphthylmethyl group is preferable, and a benzyl group, a 2-phenylethyl group, a 1-phenylethyl group or a 1-naphthyl group is preferable.
- a methyl group is more preferred.
- the substituents that the aralkyl group may have include, among the substituents described above, a cyano group, a hydroxy group, a lower alkoxy group (the lower alkoxy group).
- the group may be substituted with a halogen atom), a halogen atom, a di-lower alkylaminocarbonyloxy group, a di-lower alkylcarbamoyl group or a trifluoromethyl group, preferably a cyano group, a hydroxy group,
- a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a halogen atom or a trifluoromethyl group is more preferable.
- the aralkyl group may have the same or different 1 or 2 at the position where these substituents can be bonded.
- Examples of the “aralkyl group substituted by a cyano group” represented by R include, more specifically, a 4-cyanobenzyl group, an 1-1 (4-cyanophenyl) ethyl group, a 2- (4-cyanophenyl) ethyl group, and the like. No.
- Examples of the “aralkyl group substituted by a hydroxy group” for R include, more specifically, for example, a 4-hydroxybenzyl group, an 11- (4-hydroxyphenyl) ethyl group, and a 2- (4-hydroxy Phenyl) ethyl and the like.
- aralkyl group substituted by an alkoxy group (the alkoxy group may be substituted with a halogen atom)” represented by R, more specifically, for example, 2-methoxybenzyl group, 3-methoxybenzyl Group, 4-methoxybenzyl group, 2-
- Examples of the “aralkyl group substituted with a halogen atom” represented by R include, more specifically, a 4-chlorobenzyl group, a 1- (4-chlorophenyl) ethyl group, a 2- (4-cyclophenyl) ) Ethyl group and the like.
- the “aralkyl group substituted with an alkylaminocarbonyloxy group” represented by R is more specifically, for example, a 4- (methylcarbamoyloxy) benzyl group or a 4- (ethylcarbamoyloxy) Benzyl group, 4- (cyclopropylcarbamoyloxy) benzyl group and the like.
- Examples of the “aralkyl group substituted with a dialkylaminocarbonyloxy group” represented by R include, for example, 4- (dimethylaminocarbonyloxy) benzyl group and 4- (ethylmethylcarbamoyloxy) ) Benzyl group and 41- (ethyl carbamoyloxy) benzyl group.
- Examples of the “aralkyl group substituted by a dialkyl rubamoyl group” represented by R include, for example, a 4-dimethylcarbamoylpentyl group, a 4- (ethylmethylcarbamoyl) benzyl group, and a 2- (3-dimethyl Carbamoylphenyl) ethyl group and the like.
- the “aralkyl group substituted by an alkyl group” represented by R is, for example, a 4- (methylcarbamoyl) benzyl group, a 3- (methyl group rubamoyl) benzyl group, a 2- (methyl Carbamoyl) benzyl group, 2- (3-ethylcarbamoylphenyl) ethyl group, 2- (4-methylcarbamoylphenyl) ethyl group and the like.
- the “aralkyl group substituted with a sorbamoyl group” represented by R includes, for example, 4-force rubamoyl pendyl group, 3-force rubamoyl pendyl group, 2 Groups, 2- (3-force rubamoyl> refenyl) ethyl group and 2- (4 force rubamoylphenyl) ethyl group.
- the “aralkyl group substituted with a trifluoromethyl group” represented by R includes, for example, a 4- (trifluoromethyl) benzyl group and a 3- (trifluoromethyl) benzyl group.
- Examples of the “aralkyl group substituted by a lower alkylsulfonyl group” represented by R include, for example, 4-methansulfonylbenzyl group, 3-methanesulfonylbenzyl group, 2-methanesulfonylbenzyl group, Ethanesulfonylbenzyl, 3-ethanesulfonylbenzyl, 2-ethanesulfonylbenzyl, 2- (3-methanesulfonylphenyl) ethyl, 2- (3-methanesulfonylphenyl) ethyl, 2--( (4) methanesulfonylphenyl) ethyl group and the like.
- Examples of the “aralkyl group substituted with a cyclo-lower alkylsulfonyl group” represented by R include, for example, 4-cyclopropanemethanesulfonylbenzyl group, 3-cyclopropanemethanesulfonylbenzyl group, 2- A cyclopropanemethanesulfonylbenzyl group, a 2- (3-cyclopropanesulfonylphenyl) ethyl group, a 2- (3-cyclopropanesulfonylphenyl) ethyl group, a 2- (4-cyclopropanesulfonylphenyl) ethyl group, and the like. No. Next, the case where is a “3- to 8-membered heterocycle” will be described.
- the “3- to 8-membered heterocyclic group” represented by R in the formula (II) means a 3- to 8-membered heterocyclic ring having one or two nitrogen atoms or oxygen atoms in the ring. I do. When the hetero ring has two oxygen atoms or nitrogen atoms in the hetero ring, these hetero atoms may be the same or different.
- Examples of the 3- to 8-membered heterocyclic group include an oxenyl group, a tetrahydrofuran group, a tetrahydropyranyl group, a azetidinyl group, a pyrrolidinyl group, a piperidinyl group, a homopiperidinyl group, a morpholinyl group, a homomorphonyl group, ⁇ Lül group or homopiperazinyl group, among which oxenyl group, tetrahydrofuranyl group, tetrahydropyrael group, pyrrolidinyl group, pyridinyl group, homopiperidinyl group, morpholinyl group, and homomorphonyl group are preferred, and oxoxenyl group is preferred. Evenyl group, tetrahydrofurel group, tetrahydropyranyl group, A peridinyl group and a homopiperidinyl group are
- the substituent which the hetero ring may have includes, among the substituents described above, a cyano group, a hydroxy group, a lower alkoxy group, Group (the lower alkoxy group may be substituted with a halogen atom), a lower alkyl group (the lower alkoxy group may be substituted with a halogen atom), a halogen atom, di-lower alkylaminocarponyloxy Group, a di-lower alkylcarbamoyl group or a trifluoromethyl group, preferably a cyano group, a hydroxy group, a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a lower alkyl group (the The lower alkoxy group may be substituted with a halogen atom), a halogen atom or a trifluoromethyl group is more preferable.
- the 3 to 8 hetero rings may have one or two different positions in the same sentence at positions where these substituents can be bonded.
- the “3- to 8-membered heterocyclic ring substituted with a cyano group” represented by R is more specifically, for example, a 4-cyanoxetane-2-yl group, 4-cyanotetrahydrofuran-13-y And 3-cyanopiperidine-1-yl, 6-cyanoazepan-4-yl and the like.
- the “3- to 8-membered heterocyclic ring substituted with a lower alkyl group” represented by R is more specifically, for example, a 2-methyloxetane-13-yl group, a 2-chloromethyloxetane 1-3-yl, 4-methyloxetane-12-yl, 5-methyltetrahydrofuran-13-yl, 5-chloromethyltetrahydrofuran-13-yl, 4-methyltetrahydrofuran-12- 2-methyltetrahydropyran-1-yl, 5-methylpyrrolidine-3-yl, 4-methylpyrrolidine-3-yl, 2-methylpiperidine-1-4-yl, 3-methylpiperidine 4-yl group, 7-methylazepan-4-yl group and the like.
- Examples of the “3- to 8-membered heterocyclic ring substituted with a hydroxy group” represented by R include, for example, a 4-hydroxyoxetane-1-yl group and a 4-hydroxytetrahydrofuran-1-yl group. Examples thereof include a 3-yl group, a 3-hydroxypiperidine-4-yl group, and a 6-hydroxyazepanyl 4-yl group.
- R As the “3- to 8-membered heterocycle substituted with a halogen atom” represented by R, Specifically, for example, a 4-fluorooxetane-2-yl group, a 3-fluorooxetane-12-yl group, a 2-fluorooxetane-1-3-yl group, a 4-fluorotetrahydrofuran 1 3-yl group, 3-fluoropiperidine-4-yl group, 6-fluoroazepan-1-yl group, 4-fluorooxetane 1-2-yl group, 3-fluoroxyxetane 1-2 —Yl group, 21-chloro-oxetane-13-yl group, 4-chlorotetrahydrofuran-13-yl group, 3-chloropiperidine-4-yl group, 6-chloroazepan-4-yl group and the like.
- R Specifically, for example, a 4-fluorooxetane-2-yl
- R As the “3- to 8-membered heterocyclic ring substituted with an alkylaminocarbonyloxy group” represented by R, more specifically, for example, 4- (methylcarbamoyloxy) oxetane-1-yl group, 3 — (Methylcarbamoyloxy) oxetane— 2-yl group, 21- (ethylcarbamoyloxy) oxetane-3-yl group, 4- (methylcarbamoyloxy) tetrahydrofuran-3-yl group, 3 — (Methylcarbamoyloxy) piperidine— 4-yl group and 61- (methylcarbamoyloxy) azepan-4-yl group.
- 4- (methylcarbamoyloxy) oxetane-1-yl group 3 — (Methylcarbamoyloxy) oxetane— 2-yl group, 21- (e
- the “3- to 8-membered heterocyclic ring substituted with a dialkylaminocarbonyloxy group” represented by R is more specifically, for example, 4- (dimethylcarbamoyloxy) oxetane-1-2-f 1- (dimethylcarbamoyloxy) oxetane-12-yl group, 21- (getylcarbamoyloxy) oxetane-1-3-yl group, 4- (ethylmethylcarbamoyloxy) tetrahydrofuran-3-yl Group, 3- (dimethylcarbamoyloxy) piperidine-4-yl group, 6- (dimethylcarbamoyloxy) azepan-4-yl group and the like.
- Examples of the “3- to 8-membered heterocyclic ring substituted with an alkylrubumoyl group” represented by R include, for example, 4- (methylcarbamoyl) oxetane-2-yl group, 31- ( Methylcarbamoyl) oxetane-1-2-yl group, 4- (ethylcarbamoyl) tetrahydrofuran-3-yl group, 3- (methylcarbamoyl) piperidine-4-yl group, 61-1 (dimethylcarbamoyl) azepan-1 4-yl And the like.
- Examples of the “3- to 8-membered heterocyclic ring substituted with a carbamoyl group” represented by R include, for example, a 4-hydroxy group and a 3-hydroxy group.
- R As the “3- to 8-membered heterocyclic ring substituted with a trifluoromethyl group” represented by R, more specifically, for example, a 4- (trifluoromethyl) oxetane-12-yl group, 3 — (Trifluoromethyl) oxetane — 2-yl, 4- (trifluoromethyl) tetrahydrofuran-3-yl, 3- (trifluoromethyl) pyridin — 4-yl, 61- (trifluoro L-methyl) azepane-a 4-yl group and the like.
- a 4- (trifluoromethyl) oxetane-12-yl group 3 — (Trifluoromethyl) oxetane — 2-yl, 4- (trifluoromethyl) tetrahydrofuran-3-yl, 3- (trifluoromethyl) pyridin — 4-yl, 61- (trifluoro L-methyl) azepane
- R represents a “4- (methylsulfonyl) oxetane-2-yl group substituted with a lower alkylsulfonyl group, a 3- (ethylsilulfonyl) oxetane-2-yl group, a 4- (ethylsulfonyl) Trihydrofuran-1-yl group, 3- (methylsulfonyl) piperidine-4-yl group, 61- (methylsulfonyl) azepanyl-4-yl group and the like.
- the “3- to 8-membered heterocyclic ring substituted with a cycloalkyl lower alkylsulfonyl group” represented by R is, for example, more specifically, for example, a 4- (cyclopropylsulfonyl) oxetane-21-diphenyl group 3- (cyclopropylsulfonyl) oxetane-12-yl group, 4- (cyclopropylsulfonyl) tetrahydrofuran-13-yl group, 3- (cyclopropyl) piperidine-4-yl group, 6- (cyclopropylsulfonyl) ) Azepan-4 -yl group and the like.
- a group represented by (111-3) is more preferable in the above formula (II) or (III), when m or n of one (CH 2 ) m — or one (CH 2 ) n — is 0, one (CH 2 ) m —, one (CH 2 ) n — Means a single bond.
- one (O) j— means a single bond.
- L I represents a lower alkyl group having 1 to 4 carbon atoms or a single bond.
- L! I preferably a lower alkyl group having 1 to 3 carbon atoms or a single bond, and more preferably a lower alkyl group having 1 to 2 carbon atoms or a single bond.
- M is an oxygen atom or formula (V)
- Ro in the formula (V) represents a lower alkyl group having 1 to 4 carbon atoms.
- the Ro group include a methyl group, an ethyl group, a propyl group, an n-butyl group, an isopropyl group, an isobutyl group and a tert-butyl group.
- a methyl group, an ethyl group and a propyl group are exemplified.
- N-butyl group and isopropyl group are preferable
- methyl group, ethyl group, propyl group and isopropyl group are more preferable.
- -C! -4 Lower alkylene-1 C (0) 100_, -C 1-4 Lower alkylene-1 C (O) -N (R 0) ⁇ , — C (O) 1 N (R) ⁇ , 1 O — C 4 lower alkylene—or a single bond is preferable, and C! -4 lower alkylene group, 1 C (O) 1 O—, -C! -4 lower alkylene 1 C (0) C 1-4 lower alkylene—C (O) —N (0) —, —C ( ⁇ ) —N (R o) —, one O—C ⁇ 4 lower alkylene— or a single bond is more preferred.
- Ro has the same meaning as described above.
- Qi is a cyano group, a hydroxy group, a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group), a lower alkoxy group (the lower alkoxy group is a halogen atom , A halogen atom, a mono-lower alkylamino carboxy group, a di-lower alkylamino carboxy group, a mono-lower alkyl rubamoyl group, a di-lower alkyl rubamoyl group, a carpamoyl group, a cycloalkylimino A carbamoyl group, a lactam ring, a trifluoromethyl group, a mono-lower alkylamino group, a di-lower alkylamino group, an alkanol group, an alkoxycarbonylamino group (the nitrogen atom in the group is substituted with a lower alkyl group;
- R i and R 2 are the same or different and each represents a lower alkyl group or a mono- or di-lower alkyl group rubamoyl group, or R i and R 2 together with an adjacent nitrogen atom A 3- to 9-membered lactam ring, a heterocyclic group having 3 to 8 carbon atoms (having one or two nitrogen or oxygen atoms as constituent atoms of the group), a 5-membered heteroaryl Or a condensed heteroaryl group).
- the “linear or branched lower alkyl group” represented by Q i includes the same groups as the lower alkyl groups defined above, and among them, methyl group, ethyl group, propyl group, isopropyl group, and butyl group , Isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, neopentyl, isopentyl, 1,1-dimethylpropyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethyl Propyl, hexyl and isohexyl are preferred, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, neopentyl More preferred are an isopentyl group, a 1,1-dimethylpropyl group, a hexyl group and an
- the “linear or branched lower alkyl group” represented by the —Y more specifically, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, Isobutyl, sec-butyl, tert-butyl, ⁇ Methyl, isoamyl, neopentyl, hexyl, isohexyl, heptyl, octyl, nonanyl, decanyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec.
- examples of the substituent which the lower alkyl group may have include, among the substituents which Q i may have, Ano group, hydroxy group, lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), halogen atom, di-lower alkylaminocarbonyloxy group, di-lower alkyl group rubamoyl group, and trifluoro group A lomethyl group is preferred, and a hydroxy group, a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom) or a trifluoromethyl group is more preferred.
- Y include, for example, a 3-cyanopropyl group, a 4-cyanobutyl group, and a 2-cyanobutyl Group, 5-cyanopentyl group, 4-cyanopentyl group, 6-cyanohexyl group, 5-cyanohexyl group, 4-cyanohexyl group, 7-cyanoheptyl group, 6-cyanoheptyl group, 5-cyanoheptyl group, 8 —Cyanyl octyl group, 7—Cyanoctyl group, 6—Cyanoctyl group, 5—Cyanoctyl group, 3 _Cyanopropoxy group, 4-Cyanobutoxy group, 3-Cyanobutoxy group, 5-Cyanopentyloxy group, 4—Cyanopentyloxy group Nopentyloxy, 6-cyanohexyloxy
- —Y is more specifically, for example, a 3-hydroxypropyl group, a 4-hydroxybutyl group, 2-hydroxybutyl, 5-hydroxypentyl, 4-hydroxypentyl, 6-hydroxyhexyl, 5-hydroxyhexyl, 4-hydroxyhexyl, 7-hydroxyheptyl, 6-hydroxyheptyl Group, 5-hydroxyheptyl group, 8-hydroxyoctyl group, 7-hydroxyl oxyoctyl group, 6-hydroxyoctyl group, 5-hydroxyoctyl group, 3-hydroxypropoxy group, 4-hydroxybutoxy group, 3- Hydroxybutoxy, 5-hydroxypentyloxy, 4-hydroxypentyloxy, 6-hydroxyhexyloxy , 5-hydroxy into Kishiruokishi group, 4 Kishiruokishi group to Hidoro alkoxy, 7-hydroxy-heptyl O alkoxy group, 6-hydroxy heptene
- Y is, for example, a 3-fluoropropyl group, a 4-fluorobutyl group, or a 2-fluorobutyl group.
- Q i is a “linear or branched lower alkyl group substituted with a mono-lower alkylaminocarbonyloxy group”, more specifically, as Y, for example, 3- (methylcarbamoylo) Xy) propyl, 4- (methylcarbamoyloxy) butyl, 3- (methylcarbamoyloxy) butyl, 5- (methylcarboxy Bamoyloxy) pentyl group, 4- (methylcarbamoyloxy) pentyl group,
- the Y represented by the formula (IV) is more specifically Is, for example, 3- (dimethylcarbamoyloxy) propyl group, 4- (dimethylcarbamoyloxy) butyl group, 3- (dimethylcarbamoyloxy) butyl group, 5- (dimethylcarbamoyloxy) pentyl group, 4 1- (dimethylcarbamoyloxy) pentyl group, 61- (dimethylcarbamoyloxy) hexyl group, 5- (dimethylcarbamoyloxy) hexyl group, 4- (dimethylcarbamoyloxy) hexyl group, 2- (dimethyl Carbamoyloxy) cycloheptyl group, 7— (dimethylcarbamoyloxy) hept
- Q 1 is “a linear or branched lower alkyl group substituted with a dialkyl group rubamoyl group”, as the Y represented by the formula (IV), more specifically, for example, To 3-dimethylcarbamoylpropyl, 4-dimethylcarbamoylbutyl, 3-dimethylcarbamoylbutyl, 5-dimethylcarbamoylpentyl, 4-dimethylcarbamoylpentyl, 6-dimethylcarbamoylhexyl, 7-dimethylcarbamoyl Butyl group, 6—
- Q i is a “linear or branched lower alkyl group substituted with a trifluoromethyl group”, as the Y represented by the formula (IV), more specifically, for example, , 3- (trifluoromethyl) propyl, 4- (trifluoromethyl) butyl, 2- (trifluoromethyl) butyl, 5- (trifluoromethyl) pentyl, 4- (trifluoromethyl) 6- (Trifluoromethyl) hexyl group, 5- (Trifluoromethyl) hexyl group, 4- (Trifluoromethyl) hexyl group, 7- (Trifluoromethyl) heptyl group , 6- (trifluoromethyl) heptyl group, 5- (trifluoromethyl) heptyl group, 8- (trifluoromethyl) octyl group, 7— (trifluoromethyl) octyl group, 6- (trifluoromethyl) octyl group, 5-(Trifle (
- Examples of the ⁇ C3-C9 cycloalkyl group '' represented by Q i include the same groups as the above-mentioned C3-C9 cycloalkyl groups, and more specifically, for example, a cyclopropyl group, Cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclobutylmethyl, cyclobutylethyl, Cyclobutylpropyl, cyclobutylbutyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclohexylmethyl, cyclohexylethyl Group, cyclohexylpropyl group, cyclo
- a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclopentyl group, and the like are preferable. preferable.
- examples of the substituent that the cycloalkyl group may have include substituents that Q i may have. That is, for example, a cyano group, a hydroxy group, a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group), a lower alkoxy group (the lower alkoxy group is A halogen atom, a halogen atom, a mono-lower alkylamino propyloxy group, a di-lower alkylaminocarponyloxy group, a mono-lower alkyl rubamoyl group, a di-lower alkyl carbamoyl group, and a carbamoyl group A lactam ring, a trifluoromethyl group, a mono-lower alkylamino group, a di-lower alkylamino group or an al
- the cycloalkyl group may have one or two of these substituents at a bondable position, and when it has two of these substituents, they may be the same or different.
- Q i is a “cycloalkyl group having 3 to 9 carbon atoms” substituted with these substituents
- one Y represented by the formula (IV) is more specifically, for example,
- the phenyl group may have, among the substituents that may have, a cyano group, a hydroxy group, a lower alkyl group ( The lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group, a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a halogen atom, a mono-lower group.
- the xy group may be substituted with a halogen atom), a halogen atom, a mono-lower alkylaminocarbonyloxy group, a di-lower alkylaminocarbonyloxy group, a 'mono-lower alkyl group rubamoyl group, a di-lower alkyl group rubamoyl group Group, cycloalkyliminocarbamoyl group, lactam ring, mono-lower alkylamino group, di-lower radical A killamino group and an alkanoyl group are more preferred.
- the phenyl group may have one or two of these substituents at a position capable of binding.
- —Y represented by the above formula (IV) is more specifically, for example, a phenyl group, 4- Cyanophenyl group, 3-cyanophenyl group, 2-cyanophenyl group, 4-methoxyphenyl group, 3-methoxyphenyl group, 2-methoxyphenyl group, 4- (dimethylcarbamoyl) phenyl group, 3- (dimethylcarbamoyl) group ) Phenyl, 2- (dimethylcarbamoyl) phenyl, 4- (methylcarbamoyl) phenyl, 3- (methylcarbamoyl) phenyl, 2- (methylcarbamoyl) phenyl, 4 , 3-carbamoylphenyl group, 3-force rubamoylphenyl group, 21-strength rubamoylphenyl group, 41- (cyclopropyl-stre
- the “5- to 6-membered heteroaryl group” represented by Q i is a 5- to 6-membered ring having 1 to 3 hetero atoms in the ring selected from the group consisting of a nitrogen atom, a sulfur atom and an oxygen atom. And includes, for example, a furyl group, a chenyl group, a pyrrolyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, a thiadiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridyl group, a pyrimidinyl group, and a pyrazinyl group.
- a furyl group, a cyenyl group, a pyrrolyl group, a pyrazolyl group, a thiazolyl group, a thiadiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridyl group, a pyrimidinyl group, and a pyrazinyl group are exemplified.
- pyrazolyl Preference is given to pyrazolyl, thiazolyl, thiadiazolyl, isothiazolyl, An oxazolyl group, an isoxazolyl group, a pyridyl group, a pyrimidinyl group, and a pyrazinyl group are more preferred.
- the substituent that the heteroaryl group may have is, among the substituents that Q 1 may have, A cyano group, a hydroxy group, a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group), a lower alkyl group, a lower alkoxy group (the lower alkoxy group is a halogen atom ), A halogen atom, a mono-lower alkylaminocarbonyloxy group, a di-lower alkylaminocarbonyloxy group, a mono-lower alkyl force rubamoyl group, a di-lower alkyl force rubamoyl group, a lubamoyl group, a lactam ring And a trifluoromethyl group, a mono-lower alkylamino group, a di-lower alkylamino group and an alken
- lower alkyl group lower alkoxy
- a lower alkoxy group may be substituted with a halogen atom), a halogen atom, a mono-lower alkylaminocarbonyloxy group, a di-lower alkylaminocarbonyloxy group, a mono-lower alkylamino group, More preferred are lower alkyl rubamoyl groups, cycloalkylimino rubamoyl groups, lactam rings, mono-lower alkylamino groups, di-lower alkylamino groups, and alkanoyl groups.
- the heteroaryl group may have one or two of these substituents at a bondable position.
- Q i is a ⁇ 5- or 6-membered heteroaryl group '' which may be substituted with these substituents, as the Y represented by the formula (IV), more specifically,
- heterocyclic group having 3 to 8 carbon atoms represented by Q i means a 3- to 8-membered monocyclic ring having 1 to 2 nitrogen atoms or oxygen atoms in the ring, and the heterocyclic group is Or a group similar to the heterocyclic group having 3 to 8 carbon atoms represented by R, or the following formula (Q—l)
- R 7 represents a hydrogen atom, a lower alkyl group, a cyclo-lower alkyl group, a halo-lower alkyl group or an aralkyl group].
- the substituent which the hetero ring may have is, among the substituents which may have, a cyano group A hydroxy group, a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group), a cyclo lower alkyl group, a lower alkoxy group (the lower alkoxy group is a halogen atom Optionally substituted), halogen atom, mono-lower alkylaminocarbonyloxy group, di-lower alkylaminocarbonyloxy group, mono-lower alkyl carbamoyl group, di-lower alkylcarbamoyl group, carpamoyl group, lactam ring, Trifluoromethyl, mono-lower alkylamino, di-lower alkylamino and alkanoyl are preferred.
- a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group), a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), Halogen atom, mono-lower alkylaminocarbonyloxy group, di-lower alkylaminocarbonyloxy group, mono Lower alkyl rubamoyl, di-lower alkyl rubamoyl, cycloalkyliminocarbamoyl, lactam ring, mono-lower alkylamino, di-lower alkylamino and alkanoyl are more preferred.
- the heterocyclic group may have one or two of these substituents at a position capable of binding.
- Q 1 is optionally substituted with these groups, and is a ⁇ heterocyclic group having 3 to 8 carbon atoms '', as the Y represented by the formula (IV), more specifically,
- 1H-pyridine-2-one-4-yl group 1H-pyridine-12-one-14-yl group, 1-methyl-1H-pyridine-12-one-4-yl group, 1-ethyl-1 H_pyridine-1-one-1-yl group, 1-isopropyl-1H-pyridine-12-one-4-yl group, 1-difluoromethyl-1H-pyridine-12-one-4-yl group, 1- (2-fluoroethyl) -1-H-pyridine-1-one-4-yl group, 1- (2,2-difluoroethyl) -1-H-pyridine-2-one-1-yl group, 1- (2,2,2-triflule) 1) LH—Pyridine 1-2-one 4-yl group, 1- (2-Fluoroethoxy) — 1H—
- the substituents that the naphthyl group may have include, among the substituents that Q 1 may have, a cyano group, a hydroxy group, and a lower alkyl group.
- the lower alkyl group may be substituted with a hydroxy group, an octogen atom or an amino group
- a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a halogen atom
- the naphthyl group may have 1 or 2 at a position where these substituents can be bonded, and Q i may be substituted with these substituents.
- 1 Y is more specifically, for example, 5 -cyana naphthalene-1-yl group, 6-cyana naphthalene-11-yl group, 7-cyana naphthalene 1 1-yl group, 5-cyanonaphthalene 1-2-yl group, 6-cyanonaphthalene 1-2-yl group, 7 _cyanonaphthylene 1-2-yl group, 5-fluoronaphthalene-1-yl group, 6 -Fluoronaphthalene-1-yl group, 7-Fluoronaphthalene-1-yl group, 5-Fluoronaphthalene-12-yl group, 6-Fluoronaphthalene-12-yl group, 7-Fur Olonaphthalene-1-yl group, 5-methoxyn
- 5-trifluoromethylnaphthalene-1-yl group 6-trifluoromethylnaphthalene-1-yl group, 7-trifluoromethylnaphthyl-1-yl group, 5-trifluoromethylnaphthyl Len-2-yl group, 6-trifluoromethylnaphthalene-12-yl group, 7-trifluoromethylnaphthalene-12-yl group and the like.
- condensed heteroaryl group means a benzene ring or a pyridine ring, a 5- to 7-membered ring having 1 to 3 hetero atoms in the ring selected from the group consisting of oxygen, sulfur and nitrogen. It means a bicyclic group fused to a monocyclic ring, or a tricyclic group in which the bicyclic group is further bonded to a benzene ring or a pyridine ring.
- Examples of the "fused heteroaryl group" represented by Q 1 include a benzfuranyl group, an indolyl group, a quinolinyl group, an isoquinolinyl group, a benzoxazolyl group, a benzimidazolyl group, a phthalazinyl group, a naphthyridinyl group, and a quinoxalinyl group Quinazolinyl group, cinnolinyl group, imidazopyridinyl group, triazolopyridine group and the like.
- benzfurael group, indolyl group, quinolinyl group, isoquinolinyl group, benzoxazolyl group, benzimidazolyl group, Phthalazinyl group, naphthyridinyl group, quinoxalinyl group, quinazolinyl group, cinnolinyl group, imidazopyridinyl group and triazolopyridine group are preferred, and quinolinyl group, isoquinolinyl group, benzoxazolyl group, benzimidazolyl group, and phthalazinyl Group, naphthyridinyl group, quinoxalinyl group, quinazolinyl group, cinnolinyl group, imidazopyridinyl group and triazolopyridine group are more preferred.
- the fused heteroaryl group is examples of the substituent that may be present include, among the above substituents, a cyano group, a hydroxy group, and a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom, or an amino group); A lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a halogen atom, a mono-lower alkylaminocarbonyloxy group, a di-lower alkylaminocarbonyloxy group, a mono-lower alkylcarbamoyl group, a di-lower group Alkyl rubamoyl groups, alkamoyl groups, lactam rings, trifluoromethyl groups, mono-lower alkylamino groups, di-lower alkylamino groups and alkynyl groups are preferred, and hydroxy groups, lower alkyl
- Q 1 is a “naphthyl group” which may be substituted by these substituents, more specifically, as Y represented by the formula (IV), for example, quinoline-3-y Group, quinoline_2-yl group, 1H-indole-6-yl group, 1H-indole-17-yl group, indoline-2-one-1-yl group, indoline-12-one 1-7-yl group, 1-methylindoline 1-2-one-6-yl group, 1-methylindoline_2-one-7-yl group, 1-ethylindoline-21-one-6-yl group , 1-Ethylindoline-2-one-1-7-yl group, 1- (difluoromethyl) indoline1-2-one-6-yl group, 1- (difluoromethyl) indoline1-2-one-1-7-yl group , Quinoline-8-yl group, quinoline-1 7-yl group, dibenzofuran-13-yl group, di
- Q 1 represents a linear or branched lower alkyl group, a phenyl group, a 5- or 6-membered heteroaryl group, or a heterocyclic group having 3 to 8 carbon atoms (a nitrogen atom or an oxygen atom 1 or 2), a naphthyl group or a fused heteroaryl group
- the lactam ring when the substituent is a “lactam ring” is represented by —N (R 3) —C ( ⁇ ) — in the ring.
- R 3 represents a hydrogen atom or a lower alkyl group.
- the lactam ring may have one or two oxygen atoms or nitrogen atoms in the ring in addition to the nitrogen atom constituting —N—C (O) 1.
- the bonding position of the lactam ring bonded to is not particularly limited as long as it is a bondable position.
- T Qi which is a group represented by the formula (V-1), is a group represented by the formula (V-10) 8
- Q! Is an alkyl group having 1 to 6 carbon atoms represented by R 1 and R 2 when is a group represented by the formula (V 1), and the same linear or branched lower alkyl group as defined above.
- the lower alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, neopentyl, and hexyl.
- isohexyl groups are preferred, and methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isoamyl, neopentyl and hexyl are more preferred.
- -Y represented by, for example, an N, N-getylamino group, an N, N-dipropylamino group, an N, N-diisopropylamino group, an N, N-dibutylamino Group, N, N-dipentylamino group, N, N-dihexylamino group, N, N-diheptylamino group, N-methyl-N-ethylamino group, N-methyl-N-propylamino group, N-methyl-N- ⁇ propylamino group, N-methyl-N-butylamino group, N-methyl-N-pentylamino group, N-methyl-N-hexylamino group, N-methyl-N-heptylamino group, N -Ethy
- the “mono-lower alkyl group” represented by R 1 and R 2 is the “mono-lower alkyl group” defined above. It has the same meaning, and among these, methylcarbamoyl group, ethylcarbamo Butyl, propyl carbamoyl, isopropyl carbamoyl, butyl carbamoyl, sec-butyl carbamoyl, tert-butyl carbamoyl, methyl carbamoyl, ethyl carbamoyl, propyl carbamoyl, isopropyl rubamoyl, isopropyl rubamoyl
- the group tert-butylcarbamoyl is more preferred.
- the ⁇ di-lower alkyl group rubamoyl group '' represented by R 1 and R 2 is di-substituted by the same or different lower alkyl groups.
- di-lower alkyl group refers to, for example, a dimethylcarbamoyl group, a acetylcarbamoyl group, an ethylmethylcarbamoyl group, a dipropyl group, a methylpropyl group, a methylpropyl group, a dipropyl group. And the like.
- di-lower alkyl group includes a nitrogen atom constituting the group and an identical or different lower alkyl group bonded to the nitrogen atom.
- the “lower alkyl group or mono- or di-lower alkyl group rubamoyl group” represented by R 1 and R 2 may be the same or different.
- a lower alkyl group or a mono- or di-lower alkylcarbamoyl group More specifically, as one Y in the formula (IV), for example, an N-methyl-N- (dimethylcarbamoylmethyl) amino group, an N-methyl-N- (dimethylcarbamoylethyl) amino group, —Methyl-N— (Getyl carbamoylmethyl) amino group, N-methyl-N— (Getylcarbamoylethyl) amino group, N-methyl-1-N— (dimethylcarbamoylmethyl) aminomethyl group, N-methyl—N— ( Dimethylcarbam
- Q 1 is a group represented by the above formula (V-1), and R i and R 2 together with an adjacent nitrogen atom form a 3- to 9-membered lactam ring
- the “3- to 9-membered lactam ring” refers to a 3- to 9-membered group containing a group represented by —N—C (0) — in the ring, and One N—C ( ⁇ )
- the nitrogen atom that constitutes one one or two oxygen atoms or nitrogen atoms may be present in the ring.
- the lactam ring for example, the following formula (Q i-2) And a group represented by the following formula (Q i — 20) The group represented by is preferred.
- Y is, for example, a 1H-pyridin-2-one-1-yl group, a pyrrolidine-12-one-1-yl group, a pyridin-12-one-1-yl group, a homopyridinyl group.
- Q 1 is a group represented by the above formula (V-1), and R 1 and R 2 together with a nitrogen atom adjacent to each other form a heterocyclic ring having 3 to 8 carbon atoms
- heterocycle having 3 to 8 carbon atoms in the case of forming a heterocyclic ring means a 3- to 8-membered heterocycle having 1 or 2 nitrogen atoms or oxygen atoms as constituent atoms of the heterocycle.
- —Y in the above formula (IV) is more specifically, for example, morpholine-1-y Group, homomorpholine-1-yl group, morpholine-1-ylmethyl group, homomorpholine-1-ylmethyl group, 2- (morpholine-11-yl) ethyl group, 2- (homomorpholine-11-yl) ethyl group, 3- And a 3- (homomorpholine-11-yl) propyl group.
- L is a group represented by the above formula (V-1), and; and i together with nitrogen atoms adjacent to each other form a 5-membered heteroaryl group
- the “5-membered heteroaryl group” is a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom.
- a 5-membered monocyclic ring having 1 to 4 hetero atoms in the ring which are the same or different and selected from the group consisting of, for example, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl And pyrazole, triazole, tetrazole, oxazole, thiazol, and thiadiazole.
- pyrazole, triazole, oxazole, thiazole, and thiadiazole are more preferable.
- one Y in the above formula (IV) is more specifically, for example, a pyrazole-1-yl group, a 3-phenylpyrazole-1-yl group, or a 4-phenylpyrazol-1-yl group , 5-phenylvirazole-1-yl group, triazole-1-yl group, tetrazole-1-yl group, pyrazole-1-ylmethyl group, triazole-1-ylmethyl group, tetrazole-1-ylmethyl group, 21- (birazol-1-ylmethyl group) An ethyl group, a 2- (triazole-11-yl) ethyl group, and a 2- (tedrazol-11-yl) ethyl group.
- Q 1 is represented by the above formula (V-1), and R 1 and R 2 are a condensed heteroaryl group together with a nitrogen atom adjacent to each other; More specifically, as one Y in the above formula (IV), for example, benzimidazo
- 2-ylmethyl group imidazo [1,2, a] pyridine-6-ylmethyl group, 2- (benzimidazole-11-yl) ethyl group, 2- (benzotriazole-11-yl) ethyl group, 2- (benzotriazole-2-yl) ethyl group; and 2- (imidazo [1,2, a] pyridine-16-yl) ethyl group.
- the compound (I) according to the present invention for example, 2- (1-cyclopentylpiperidine-4-1yloxy) -5- (4-cyanophenyl) pyrimidine, 21- (1-isopropyl) Pyridine-1 4 1 ⁇ -peroxy) -5- (4-Cyanophenyl) pyrimidine, 2- (1-cyclopentylpyrrolidine-3-yloxy) 1 5- (4-Lubamoylphenyl) pyrimidine, 2- (1-cyclopentylpyrrolidine—3-yloxy) -5- (4-cyanophenyl) pyrimidine, 2- (1-cyclopentylpiperidine—4-yloxy) 1 5— ⁇ (3-methyl-1,1,2,4-oxaziazio) 5- (yl) phenyl ⁇ pyrimidine, 2- (1-cyclopentylbiperidine-1-41 ⁇ f-roxy) -5- (4-cyanophenyl) pyridine,
- the compound (I) according to the present invention is a histamine H 3 receptor antagonist or an insulin gonist. It acts as a bar sagonist.
- histamine receptor H3 inverse agonist is a receptor-binding substrate having a completely or partially opposite action to histamine receptor H3 agonist. It means a ligand that suppresses constitutive activity.
- the compound (I) according to the present invention can be easily produced using a known reaction means or according to a method known per se.
- the compound (I) according to the present invention can be produced not only by a general synthesis method in a liquid phase but also by a method using a solid phase such as a combinatorial synthesis method or a parallel synthesis method which has been remarkably developed in recent years. Can be.
- the compound according to the present invention can be produced, for example, by the following method.
- m represents an integer of 0 to 3, 1 is a cyano group, a hydroxy group, a lower alkyl group (the lower alkyl group may be substituted with a hydroxy group, a halogen atom or an amino group)),
- a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a halogen atom, a mono-lower alkylaminocarbonyloxy group, a di-lower alkylaminocarbonyloxy group, a mono-lower alkylcarbamoyl group, a di-lower group Selected from the group consisting of alkyl rubamoyl, carbamoyl, cycloalkylimino propylonyl, and trifluoromethyl
- a linear or branched lower alkyl group (excluding a methyl group), a cycloalkyl group having 3 to 9 carbon atoms, an aralkyl group, or a heterocyclic group having
- L i represents a lower alkylene group having 1 to 4 carbon atoms or a single bond
- M represents an oxygen atom or a formula (V)
- RQ represents a lower alkyl group having 1 to 4 carbon atoms
- Q i represents a cyano group, a hydroxy group, or a lower alkyl group
- the lower alkyl group is a hydroxy group
- a lower alkoxy group (which may be substituted with a halogen atom), a lower alkylsulfonyl group, a cyclo-lower alkylsulfonyl group, a halogen atom, , Mono-lower alkylaminocarbonyloxy group, di-lower alkylaminocarbonyloxy group, mono-lower alkyl force rubamoyl group, di-lower alkyl force rubamoyl group, force rubamoyl group, cycloalkyliminocarbamoyl group, lactam ring, tri A linear or branched lower alkyl group which may be substituted with a group selected from the group consisting of a fluoromethyl group, a mono-
- R i and R 2 are the same or different and each represents a lower alkyl group or a mono- or di-lower alkyl group rubamoyl group, or R 1 and R 2 are taken together with an adjacent nitrogen atom.
- the general organometallic atom of Met means an organometallic atom generally used in a cross-coupling reaction, for example, lithium, boron, silicon, magnesium, aluminum, zinc, tin, etc., more preferably boron, Specific examples of usage include boron as boric acid or borate ester, zinc as zinc chloride, zinc bromide or zinc iodide, and tin as tri-lower alkyltin. Are mentioned.
- any leaving group may be used as long as it has a function of leaving in the reaction between the above formulas (VI) and (VI I).
- any leaving group may be used as long as it has a function of leaving in the reaction between the above formulas (VI) and (VI I).
- chlorine atom, bromine atom or iodine atom, etc. octalogen atom, methanesulfonyl group, ethanesulfonyl group, benzenesulfonyl group, etc.
- examples thereof include organic sulfonyl groups, organic sulfonyloxy groups, trifluoromethanesulfonyloxy groups, and organic sulfonyloxy groups such as P-toluenesulfonyloxy group.
- the compound (VII) is usually used in an amount of 0.5 mol to 5 mol per 1 mol of the compound (X). And preferably from 0.7 mol to 3 mol.
- the catalyst used in the reaction examples include transition metals generally used in a cross-coupling reaction such as copper, nickel, and palladium, and more specifically, tetrakis (triphenylphosphine) palladium (0), palladium ( II) Acetate, bis (triphenylphosphine) palladium (II) chloride, [1,1,1-bis (diphenylphosphino) phenyl] palladium (II) dichloride and the like are preferable.
- transition metals generally used in a cross-coupling reaction such as copper, nickel, and palladium
- tetrakis (triphenylphosphine) palladium (0), palladium ( II) Acetate, bis (triphenylphosphine) palladium (II) chloride, [1,1,1-bis (diphenylphosphino) phenyl] palladium (II) dichloride and the like are preferable.
- the reaction is usually performed in an inert solvent.
- inert solvent examples include water, benzene, toluene, xylene, methylene chloride, chloroform, dimethoxyethane, tetrahydrofuran, dioxane, dimethylformamide and the like or a mixture thereof. Solvents and the like are preferred.
- the reaction temperature is usually from room temperature to the boiling point of the solvent used in the reaction, preferably from 20 ° C to 200 ° C.
- the reaction time is generally 30 minutes to 7 days, preferably 3 hours to 2 days.
- the above reaction is preferably carried out in the presence of a base.
- the base include inorganic bases such as sodium hydroxide, ⁇ potassium oxide, sodium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate, and the like, triethylamine, diisopropylamine And the like.
- the amount of the base to be used is generally 0.5 to 5 mol, preferably 0.7 to 3 mol, per 1 mol of the compound represented by the general formula (VI). .
- the compound of the present invention (1- 2) or the compound of (1-3) can be produced.
- the compound (1-2) or (I-13) according to the present invention thus obtained can be obtained by a known separation and purification means, for example, concentration, concentration under reduced pressure, recrystallization, reprecipitation, solvent extraction, and chromatography. Can be isolated and purified.
- the compound represented by the formula (VI), (VII), (IX) 'or (X) may be, for example, a commercially available product, a known method or a method analogous thereto, or described in Examples and Reference Examples. It can be manufactured by appropriately combining the methods described above as needed.
- the “protecting group for an amino or imino group” is not particularly limited as long as it has the function thereof. Examples thereof include a benzyl group, a P-methoxybenzyl group, a 3,4-dimethoxybenzyl group, and an o-nitrobenzyl group.
- Aralkyl groups such as p-nitrobenzene group, benzylhydryl group, and trityl group; lower alkanoyl groups such as formyl group, acetyl group, propionyl group, butyryl group and piperoyl group; benzoyl group; Arylalkanol groups such as enoxyacetyl group; lower alkoxycarbonyl groups such as methoxycarbonyl group, ethoxycarbonyl group, propyloxycarbonyl group, tert-butoxycarbonyl group; and benzyloxycarbonyl group; Nitrobenziloxy carbonyl group, phenene Aralkyloxypropyl groups such as a tyloxypropyl group; lower alkylsilyl groups such as a trimethylsilyl group and tert-butyldimethylsilyl group; a tetrahydroviranyl group; a trimethylsilylethoxymethyl group; a methylsulf
- the “protecting group for the hydroxy group” is not particularly limited as long as it has the function thereof.
- a lower alkyl group such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a tert-butyl group; a trimethylsilyl group; a lower alkylsilyl group such as a tert-butyldimethylsilyl group; a lower alkoxymethyl group such as a methoxymethyl group or a 21-methoxyethoxymethyl group; a tetrahydropyrael group; such as a trimethylsilylethoxymethyl group;
- Aralkyl groups such as P-methoxybenzyl group, 2,3-dimethoxybenzyl group, o-nitrobenzyl group, p-nitrobenzyl group, and trityl group; for example, acyl groups such as formyl group and acetyl group In particular, methyl
- the “protecting group for the carboxyl group” is not particularly limited as long as it has the function.
- a lower alkyl group such as a methyl group, an ethyl group, a propyl group, an isopropyl group and a tert-butyl group; Halo-lower alkyl groups such as 2,2-trichloromethyl group; lower alkenyl groups such as 2-propenyl group; benzyl group, p -methoxybenzyl group, p -nitrobenzyl group, benzhydryl group, trityl group And the like, and particularly preferred are a methyl group, an ethyl group, a tert-butyl group, a 2-propenyl group, a benzyl group, a p-methoxybenzyl group, a benzylhydryl group and the like.
- the “protecting group for an oxo group or a carbonyl group” is not particularly limited as long as it has the function, and examples thereof include acetal such as ethylene ketal, trimethylene ketal, and dimethyl ketal, and ketal.
- the compound according to the present invention can also be produced, for example, by the following method. Manufacturing method 2
- Xi, ⁇ 2, X 3, ml, ⁇ and ⁇ are as defined above] can be produced represented by reduction compounds with.
- the compound (X) is usually used in an amount of 0.5 mol to 5 mol based on 1 mol of the compound (IX). It is preferably carried out using 0.7 mol to 3 mol.
- Examples of the catalyst used in the reaction include transition metals generally used in cross-coupling reactions such as copper, nickel, and palladium. More specifically, tetrakis (triphenylphosphine) palladium (0), palladium ( II) Acetate, bis (triphenylphosphine) palladium (II) chloride, [1,1, —bis (diphenylphosphino) phenacene] palladium (II) dichloride and the like are preferable.
- transition metals generally used in cross-coupling reactions such as copper, nickel, and palladium. More specifically, tetrakis (triphenylphosphine) palladium (0), palladium ( II) Acetate, bis (triphenylphosphine) palladium (II) chloride, [1,1, —bis (diphenylphosphino) phenacene] palladium (II) dichloride and the like are preferable.
- the reaction is usually carried out in an inert solvent.
- the inert solvent include water, benzene, toluene, xylene, methylene chloride, chloroform, dimethoxyethane, tetrahydrofuran, dioxane, dimethylformamide and the like.
- the mixed solvent is suitable.
- the reaction temperature is usually from room temperature to the boiling point of the solvent used in the reaction, preferably from 20 ° C to 200 ° C.
- the reaction time is generally 30 minutes to 7 days, preferably 3 hours to 2 days.
- the above reaction is preferably performed in the presence of a base.
- the base include inorganic bases such as sodium hydroxide, potassium hydroxide, sodium hydrogen carbonate, sodium carbonate, potassium carbonate, and cesium carbonate; triethylamine; diisopropylethylamine. And the like.
- the amount of the base to be used is generally 0.5 to 5 mol, preferably 0.7 to 3 mol, per 1 mol of the compound represented by the general formula (IX). .
- the compound is subjected to a usual treatment to produce the compound of the present invention.
- Removal of the protecting group, post-treatment, and the like can be performed according to the method described in the above-mentioned Production Method 1.
- the compound represented by formula (X) can be produced by a known method or a method analogous thereto, or by appropriately combining the methods described in Examples and Reference Examples as needed.
- the compound according to the present invention can also be produced by the following method. Manufacturing method 3
- R ii represents R i or an amino-protecting group, and other symbols have the same meanings as described above), or a group represented by the formula (III)
- the compound of the general formula (I), (I-12) or (I_3), which is a compound according to the present invention, can be easily isolated and purified by ordinary separation means.
- Such means include, for example, solvent extraction, recrystallization, reprecipitation, column chromatography, preparative thin layers: One example can be exemplified.
- the heteroaryloxy nitrogen-containing saturated heterocyclic derivative according to the present invention can exist as a pharmaceutically acceptable salt, and the compound represented by the formula (I) can be produced by a conventional method. can do.
- the acid addition salt include hydrooctylates such as hydrochloride, hydrofluoride, hydrobromide, and hydroiodide; nitrates, perchlorates, sulfates, phosphates, and the like.
- Inorganic acid salts such as carbonate; lower alkylsulfonic acid salts such as methanesulfonic acid salt, trifluoromethanesulfonic acid salt and ethanesulfonic acid salt; arylsulfonic acids such as benzenesulfonic acid salt and p-toluenesulfonic acid salt Salts; organic acid salts such as fumarate, succinate, citrate, tartrate, oxalate and maleate; and acid addition salts such as amino acids such as glutamate and aspartate. Can be mentioned.
- the base addition salt examples include alkali metal salts such as sodium and potassium, alkaline earth metal salts such as calcium and magnesium, ammonium salts, salts with organic bases such as guanidine, triethylamine, and dicyclohexylamine.
- the compounds of the present invention may exist as any hydrates or solvates of the free compounds or salts thereof.
- the cDNA sequence encoding the human histamine 3 receptor [see International Patent Application WO00 / 39164] was added to the expression vectors PCR2.1, EF1x (manufactured by Invitrogen) and (31_1160 (manufactured by Promega)).
- the resulting expression vector was cloned into a cationic lipid method [Proceeding of the National Academy of Sciences, Ob, The United, Steadov, USA] (Proceeding soft he nati on alac ad e my ofscie nc esoft he un itedsta tesof America), Vol. 84, p. 7413 (1987)], and transfected into host cells, HEK293 and CHO-K1 (American 'type' culture 'collection), and cells expressing histamine 3 receptor were transfected. Obtained.
- a membrane sample prepared from cells expressing the histamine 3 receptor was combined with a test compound and 20,000 cpm of H] N-a-methhylhistamine (NEN) together with an Atssey buffer ( After incubation in 5 OmM Tris buffer, pH 7.4) at 25 ° C for 2 hours, the mixture was filtered through a glass filter GFZC. After washing with 5 OmM Tris buffer and H7.4, the radioactivity on the glass filter was determined. Non-specific binding was measured in the presence of 10 / M thioperamide (manufactured by SI GAM), and the 50% inhibitory concentration (IC 50 value) of the test compound against specific N- ⁇ -methyhistamine binding was determined. (See Molecular Pharmacology, 55, 1101 (1999)). As a result, the IC so value of the compound of Example 1 was 15 nM.
- a membrane preparation prepared from cells expressing the histamine 3 receptor was treated with a test compound, 20 nM R-methy 1 histamine (histamine analog, manufactured by Sigma), 10 M GDP (guanine nucleotide diphosphate, Sigma), 200 pM
- [5S] GTPr S (guanine nucleotide triphosphate analog, manufactured by Amersham), S PA resin (W heatge rm agg lutinin SPA beads, manufactured by Amersham), and Atzey buffer (5 OmM Tris buffer, 100m) M NaCl, 5 mM MgCl 2 , pH 7.4 25) at 96 ⁇ Eroptiplate (Packard). C, incubated for 3 hours, centrifuged at 300 rpm, and the activity was determined by TopCount (Packard).
- the compounds of the present invention potently inhibited the binding of N-methyhistamine (histamine analog) to the hisminamine 3 receptor.
- Pharmacological Test Example 3 Antagonism test on drinking behavior induced by R- ⁇ -methhy 1 histamine, a histamine 3 receptor selective agonist
- Under ketamine / xylazine anesthesia (74 and 1 lmgZkg single intraperitoneal injection)
- a male SD rat (7-10 weeks old, 200-300 g) was inserted into the third ventricle using a stereotaxic device to insert a chronic guide force neura (26 gauge, 11 mm long). And fixed with resin.
- the position of the tip of the guide cannula was 2.2 mm behind the bregma, on the midline, and 8 mm deep from the skull surface.
- R-a-methylhistamine 0.3 g / 1 L / head, 30% propyleneglycol solution
- the test compound suspended in 0.5% methylcellulose aqueous solution was orally administered 2 hours before the administration of R—Q! —Methhy 1 histamine, and the R— ⁇ —methy 1 histamine was administered. One hour later, the amount of drinking water was measured.
- the compound of the present invention significantly suppressed the increase in water consumption due to R-1 methy1 istamine administered into the third ventricle at 1 OmgZkg.
- Pharmacological test example 4 (Pharmacokinetic test) ⁇ ⁇ The test compound is orally or intravenously administered to fasted male SD rats (7 to 10 weeks old, 200 to 400 g), and at predetermined time, using tailored caviali via the tail vein. About 100 L of blood was collected. Blood was centrifuged (4 ° C, 6000 rpm, 10 minutes) to obtain plasma. Three times the amount of ethanol (including the internal standard substance) was added to the plasma, stirred, left at 20 ° C for 20 minutes, and centrifuged (4C, 10,000 rotations, 10 minutes). The supernatant was analyzed by LC / MS / MS, and the plasma concentration was quantified by the relative calibration curve method.
- Example 1 had a bioavailability of 53% and a half-life in blood of 5.3 hours.
- Pharmacological test example 5 (brain / cerebrospinal fluid migration test)
- test compound was orally or intravenously administered to male SD rats (7-10 weeks old, 200-400 g), and whole blood was collected from the abdominal aorta using a heparin-treated syringe under ether anesthesia at a predetermined time. did. After that, the skin of the head was incised, 30 G ⁇ for dental use was inserted into the cervical vertebra, and further inserted into the subarachnoid space. The cerebrospinal fluid of 50-10 O L was collected through a tube connected to a dental 30G needle into an lmL syringe, and the brain was removed.
- the blood sample was centrifuged (4 ° C, 6000 rpm, 10 minutes), and three times the amount of ethanol (including the internal standard) was added to the plasma and stirred.
- the brain sample was homogenized by adding 2 mL of water, a portion was taken, and three times the amount of ethanol (including the internal standard) was added and stirred.
- the cerebrospinal fluid was mixed with 3 volumes of ethanol (including the internal standard) and stirred.
- the above sample was left at -20 ° C for 20 minutes, centrifuged (4 ° C, 12,000 g, 10 minutes), and the supernatant was analyzed by LCZMSZMS. The concentrations in the brain and cerebrospinal fluid were quantified.
- the compound of Example 1 showed a brain concentration of 6.18 nmolZg, a cerebrospinal fluid concentration of 0.128 ⁇ M, and a plasma concentration of 0.54 two hours after oral administration (10 mg / kg). .
- the compound represented by the general formula (I) can be administered orally or parenterally, and when formulated into a form suitable for such administration, it can be used for obesity, diabetes, and hormone secretion. Abnormalities, hyperlipidemia, gout, metabolic diseases such as fatty liver, etc.
- Angina pectoris acute and depressive heart failure, myocardial infarction, atherosclerosis, hypertension, kidney disease, various disorders with sleep disorders and sleep disorders, such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia Syndrome, narcolepsy, periodic limb movement disorder during sleep, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, elderly insomnia, night shift sleep insanity, idiopathic insomnia, repetitive Cardiovascular diseases such as insomnia, intrinsic insomnia, and electrolyte abnormalities, such as bulimia, affective disorder, depression, anxiety, epilepsy, delirium, dementia, schizophrenia, attention deficit * hyperactivity disorder, memory disorder, and Alzheimer's Preventive or therapeutic agent for central and peripheral nervous system diseases such as Parkinson's disease, Parkinson's disease, sleep disorder, cognitive disorder, movement disorder, paresthesia, olfactory disorder, epilepsy, morphine resistance, drug dependence, and alcohol dependence For the purpose that you provide.
- the compound of the present invention When used clinically, it can be administered after formulating various preparations by adding pharmaceutically acceptable additives according to the dosage form.
- Various additives usually used in the field of pharmaceutical preparations can be used in this case, such as gelatin, lactose, sucrose, titanium oxide, starch, crystalline cellulose, hydroxypropylmethylcellulose, propyloxymethylcellulose, and corn starch.
- Microcrystalline wax white petrolatum, magnesium metasilicate aluminate, calcium phosphate anhydrous, citric acid, trisodium citrate, hydroxypropylcellulose, sorbitan], sorbitan fatty acid ester, polysorbate, sucrose Fatty acid esters, polyoxyethylene, hydrogenated castor oil, polipinylpyrrolidone, magnesium stearate, light caffeic anhydride, talc, vegetable oil, benzyl alcohol, gum arabic, propylene glycol , It includes the polyalkyl down, and the like.
- Dosage forms formulated as a mixture with these additives include solid preparations such as tablets, capsules, granules, powders and suppositories; or liquids such as syrups, elixirs and injections Preparations and the like can be mentioned, and these can be prepared according to a usual method in the field of preparations.
- a liquid preparation it may be in the form of being dissolved or suspended in water or another appropriate medium before use.
- injections they can be dissolved or suspended in physiological saline or dextrose as necessary.
- a buffer and a preservative may be added.
- formulations may contain the compounds of the present invention in a proportion of from 1.0 to 100% by weight, preferably from 1.0 to 60% by weight of the total drug. These formulations may also contain other therapeutically effective compounds.
- the compounds of the present invention can be used in combination with other agents useful for treating metabolic disorders and Z or eating disorders.
- the individual components of such combinations can be administered in divided or single dosage forms during the treatment, at different times or simultaneously.
- the present invention should be construed to include all administrations, either simultaneously or at different times, and administrations in the present invention should be construed accordingly.
- the range of the combination of the compound of the present invention and another drug useful for treating a metabolic disorder and / or an eating disorder is, in principle, a combination with a metabolic disorder and Z or any pharmaceutical preparation useful for treating an eating disorder. Are also included.
- the compound of the present invention is a drug effective for hypertension, hypertension related to obesity, hypertension-related disease, cardiac hypertrophy, left ventricular hypertrophy, metabolic disease, obesity, obesity-related disease and the like (hereinafter referred to as “combination drug”). ) Can be used in combination. Such drugs can be administered simultaneously, separately or sequentially in the prevention or treatment of the aforementioned diseases. When the compound of the present invention is used contemporaneously with one or more concomitant drugs, it can be made into a pharmaceutical composition as a single dosage form. However, in combination therapy, the composition containing the compound of the present invention and the concomitant drug may be administered to the subject in different packages, simultaneously, separately or sequentially. They may be administered at staggered times.
- the dose of the concomitant drug may be in accordance with the dose clinically used, and can be appropriately selected depending on the administration target, administration route, disease, combination and the like.
- the administration form of the concomitant drug is not particularly limited as long as the compound of the present invention and the concomitant drug are combined at the time of administration.
- Such administration forms include, for example, 1) administration of a single preparation obtained by simultaneously formulating the compound of the present invention and a concomitant drug, and 2) separate administration of the compound of the present invention and the concomitant drug.
- concomitant drug used in the present invention examples include a "diabetic drug”, a “hyperlipidemic drug”, a “hypertensive drug”, an “antiobesity drug” and the like. Two or more of these concomitant drugs may be used in combination at an appropriate ratio.
- anti-diabetic agent examples include: 1) glidazones (g 1 it az on es) [for example, cigli dazone (cig 1 itazone), dalgli dazone (darg 1 itaz on e), enclitazone, eng lit az one), isa Daridazon (is ag litaz one) (MC C-555) etc.), piodari evening (piog 1 itaz one), mouth siglidazone (rosig 1 itazone), troglitazone (tro 1 itaz one), BRL 49653, C LX-0921, 5—P PAR agonists such as BTZD, GW-0207, LG-100641, LY—300512; 2) Biguanides such as metformin (metformin), buformin, phenformin; 3) Protein tyrosine phosphatase -1B inhibitor; 4) acetohexamide,
- repaglinide rep ag lini de
- meglitinides such as nateglinide (nateg 1 inide); 6) acarbose, adiposin (ad iposi ne), force miglipose (cami 1 ibose), emiglitate (em ig 1 itate), Miglito (Mig 1 ito 1), poglipois (vog 1 ib), pradimicin-Q (pradimicin-Q), sarpostatin (sa 1 ostatin), CKD-711, MDL- 25, 673, MDL-73, 945, M ⁇ R 14 etc.
- Linodalide 1 inog 1 iride
- an insulin secretagogue such as A-4166
- chromoxyl c 1 omo Xir
- etomoxil et omox ir
- other fatty acid oxidation inhibitors 10) midaglizole (midag 1 izo 1) e), A2 angst gonists such as isagridol (isag 1 ido 1 e), deliglidol (de rigli do le), idazoxan, idolaxan, earoxan, flupar ox an; 1 1) Biota, LP-100, Novalapid, insulindet emir, insulin 1 ispr o> insu 1 ingl argine, insulin zinc, Lys_Pro—insulin
- hypolipidemic agent examples include: 1) cholesterylamine, colesevelem, colestipol, colestipol, dialkylaminoalkyl derivatives of cross-dextran, Co 1 estid registered trademark, L o C Bile acid absorption enhancers such as ho 1 est registered trademark and Questran registered trademark; 2) atorvastatin (itavastatin), fluvastatin (fl uv astatin), lovastatin (l) ov astatin), pravastatin, rivastatin, rosuvastatin, simvastatin, ZD-4522, etc.
- MG—Co A reductase inhibitor 3) HMG—CoA synthesis inhibitor; 4) Sunitol ester, cholesterol absorption inhibitor such as) 3-sitosterol, sterol darcoside, ezetimibe; 5) Avasimibe (Av as imi be), eflucimibe, KY-505, SMP-709, etc., and isolcoenzyme A cholesterol-acyltransferase inhibitors; 6) JTT 705, torcetrapib, CP .532632, BAY-63-2149, SC-591, SC-795, etc .; CETP inhibitors; 7) Squalene synthesis inhibitors, 8) Antioxidants, such as propol, 9) Beclofibrate, Benzafibrate, Ciprofibrate, Clofibrate, Etofibrate, Fuenofibrate, Gen emb abene, Genfib brozil (Gemf ibrozi 1), GW-7647, BM-170744
- hypotensive agent examples include: 1) thiazides such as clothiariadone, chlorothiazide, dichlorophenamide, hydrofluorothiazide, indapamide (indapamide), hydroclochia thiazide; bumetanide (b time tanide), ethacrynic acid ⁇ loop system such as furosemid, torsemide, etc., sodium system such as amicolide, triamterene, etc., diuresis such as spironolactone, eposterone, etc. aldosterone angiogonist system.
- thiazides such as clothiariadone, chlorothiazide, dichlorophenamide, hydrofluorothiazide, indapamide (indapamide), hydroclochia thiazide
- bumetanide b time tanide
- ethacrynic acid ⁇ loop system such as furosemid, torsemide, etc.
- Indropri Ripanipril (quanipri 1), Subirapril (spirapri 1), Tenocaprinole (tenocapril), Trandolapril (tr ando lapri 1), Zofenopril (zof enop ri) 1) angiotensin converting enzyme inhibitors such as 5) omapatrilat (oma patri 1 at), dexoxatril (cadoxatri 1), ecadotril, fosidotril (fosi do tril), sampatrilat (samp atri 1 at), AVE 7688 ER4030, neutral endopeptidase inhibitors; 6) tezosentan, A308165, YM62899, etc.
- endothelin antagonist 7) hydralazine, clonidine, minoxidil, nicochel alcohol, etc.
- Vasodilators candesartan, eprosartan, irbesartan, oral sultan, pratosartan, tasosartan, telmisartan (e1) misart an), palsartan, EXP-3137, angiotensin II antagonists such as FI 6828 RNH6270; 9) ⁇ / 3 adrenaline blockers such as nipradilol, arotinolol, and amoslarol; 10) terazosin, ⁇ rapidil (urapidi 1), brazosin ⁇ 1 blockers such as bunazosin, trimazosin, doxazosin, naftopidil, indolamine, WHI P164, XEN010;
- ⁇ 2agonist such as oral fexidine (lofexidine), thiamenidine (tiaminedine), moxonidine (moxonidine), hydrogen chloride (ri1menidine), guanoben (guanobenz);
- antiobesity drug examples include 1) paroxetine (par ox etine;), fluoxetine (fl uoxe tine), fenfluramine en f 1 ur ami ne, flupoxamine (fl uvoxami ne), sertraline (sertra 1) ine), 5HT (serotonin) transporter inhibitor such as imipramine; 2) norepinephrine transporter inhibitor such as GW320659, desibramine, evening spram, nomifensin; 3) rimonabant ( S ano ii Syn t he l abo), SR-147778 (S ano fi Syn tel abo), BAY— 65-2520 (Bayer), S LV-319 (Solvey), other USP 5,532,237, USP 4,973,587, USP 5,0 13,837, USP 5,081,122, US P 5,1 12, 820, USP 5, 292, 736, USP
- CB-1 cannabinide 1 receptor 1
- Dareline antagonists such as compounds disclosed in WO 01/87355, WO 02/08250, etc .
- NPY 5 antagonists such as the compounds disclosed in (2000); 10) Human recombinant leptin (PEG-OB, Hoffman La Roche), recombinant methionyl leptin ( 11) USP 5,552, 524, USP 5, 552, 523, USP 5, 552, 522, USP 5, 521, 283, WO 96/23513, WO 96/2 3514, WO 96/23515, WO 96/23516, WO 96/2351 7, WO 96/23518, WO 96/23519 and WO 96/23520, lebutin derivatives such as the compounds disclosed therein; 12) nalmefene (Re vex®), 3-methoxynaltrexone, naloxone, naltrexone, opioid antagonists such as the compounds disclosed in WO00 / 21509; 13) SB_334867A, others WO 01/96302, WO 01
- Serotonin receptor 2 C agonist such as compounds disclosed in WO 02/44152, WO 02/5 1844, WOO 2/40456 and WO 02/40457; 20) Melanocortin 3 receptor Agonist; 21) CH IR 86036 (Chiron), ME-10142, ME-10145 (Me1acure), other W ⁇ 99 / 64002, WO00 / 74679, WO01 / 991752, WOO1 / 74844, WOO 1/7
- valine pyrrolidide such as the compounds disclosed in 003/000181; 39) Tetrahydroributin (registered trademark of orlistat / Xenical), Triton WR 1339, HC 80267, Libstatin, teas aponin ), Detyl hyn umbe l 1 ife ry l pho
- the combination drug can be obtained by using one or more of the compound of the present invention and the combination drug in combination.
- the combination drug is useful for preventing or treating a metabolic disease by combining it with one or more drugs selected from the group consisting of a drug for treating diabetes and a drug for treating hyperlipidemia.
- a combination containing a therapeutic agent for hypertension and an antiobesity agent is useful for the prevention or treatment of metabolic diseases with a synergistic effect by adding a therapeutic agent for diabetes and a therapeutic agent for Z or hyperlipidemia.
- the dosage and frequency of administration vary depending on the patient's sex, age, body weight, degree of symptoms, and the type and range of the intended treatment effect.
- a routine physician, veterinarian, or clinician may be able to stop, inhibit, or arrest the progress of the condition.
- the required effective drug amount can be easily determined and processed.
- the thin-layer chromatograph of the example used Si1cage160F245 (Merck) as a plate and a UV detector as a detection method.
- Wakogel C-300 (Wako Pure Chemical Industries) is used as the silica gel for the column, and LC-SORB S PB-ODS (Chemco) or YMC—GEL ODS-AQ 120 -S 50 ( Yamamura Chemical Laboratory) was used.
- the mass vector is Quat tro ll (Micromass).
- n-Pr n-propyl group
- the title compound was obtained by performing the same reaction as in Example 11-1) using 2-chloro-5-bromopyrimidine and 4-hydroxy-1-cyclopentyl piperidine.
- the title compound was obtained in the same manner as in Example 1 except for using 5-indolylporonic acid instead of 4-cyanophenylporonic acid.
- the title compound was obtained in the same manner as in Example 17 by using 2- (1-cyclopentylbiperidine-14-yloxy) -15-bromopyrimidine and piperidin-2-one.
- the title compound was obtained in the same manner as in Example 1, except that 4- (trifluoromethyl) phenylporonic acid was used in place of 4-cyanophenylporic acid.
- the title compound was obtained in the same manner as in Example 1 except for using 4-methoxyphenylporonic acid instead of 4-cyanophenylporonic acid.
- the title compound was obtained in the same manner as in Example 1 except for using 4- (methylsulfonyl) phenylporonic acid instead of 4-cyanophenylporonic acid.
- the title compound was obtained in the same manner as in Example 1 except for using 4-acetylphenylporonic acid instead of 4-cyanophenylporonic acid.
- Example 62-1 The synthetic intermediate obtained in Example 62-1) and 3-chloro-5-odo-1-methyl
- the title compound was obtained in the same manner as in Examples 48-2) and 3) using 1-1H-pyridin-2-one.
- the heteroaryloxy-nitrogen-containing saturated heterocyclic derivative or a pharmaceutically acceptable salt thereof according to the present invention represented by the above formula (I) has a strong histamine receptor H3 agonist or inverse agonist activity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002529790A CA2529790A1 (en) | 2003-06-27 | 2004-06-24 | Heteroaryloxy nitrogenous saturated heterocyclic derivative |
EP04746741A EP1642898B1 (en) | 2003-06-27 | 2004-06-24 | Heteroaryloxy nitrogenous saturated heterocyclic derivative |
US10/561,115 US7595316B2 (en) | 2003-06-27 | 2004-06-24 | Heteroaryloxy nitrogenous saturated heterocyclic derivative |
AU2004257025A AU2004257025B9 (en) | 2003-06-27 | 2004-06-24 | Heteroaryloxy nitrogenous saturated heterocyclic derivative |
JP2005511807A JP4735261B2 (ja) | 2003-06-27 | 2004-06-24 | ヘテロアリールオキシ含窒素飽和ヘテロ環誘導体 |
US12/540,534 US8044070B2 (en) | 2003-06-27 | 2009-08-13 | Heteroaryloxy nitrogenous saturated heterocyclic derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-184879 | 2003-06-27 | ||
JP2003184879 | 2003-06-27 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10561115 A-371-Of-International | 2004-06-24 | ||
US12/540,534 Division US8044070B2 (en) | 2003-06-27 | 2009-08-13 | Heteroaryloxy nitrogenous saturated heterocyclic derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005007644A1 true WO2005007644A1 (ja) | 2005-01-27 |
Family
ID=34074295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/009272 WO2005007644A1 (ja) | 2003-06-27 | 2004-06-24 | ヘテロアリールオキシ含窒素飽和へテロ環誘導体 |
Country Status (7)
Country | Link |
---|---|
US (2) | US7595316B2 (ja) |
EP (1) | EP1642898B1 (ja) |
JP (1) | JP4735261B2 (ja) |
CN (1) | CN1812981A (ja) |
AU (1) | AU2004257025B9 (ja) |
CA (1) | CA2529790A1 (ja) |
WO (1) | WO2005007644A1 (ja) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006059778A1 (ja) * | 2004-12-01 | 2006-06-08 | Banyu Pharmaceutical Co., Ltd. | 置換ピリドン誘導体 |
WO2006129826A1 (ja) * | 2005-05-30 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
EP1814551A2 (en) * | 2004-09-20 | 2007-08-08 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
WO2008072703A1 (ja) * | 2006-12-14 | 2008-06-19 | Taisho Pharmaceutical Co., Ltd. | ビフェニルアミド誘導体 |
JP2008534572A (ja) * | 2005-04-01 | 2008-08-28 | ビオポロジェ | 非イミダゾールアルキルアミンヒスタミンh3−受容体リガンドによるパーキンソン病、閉塞性睡眠時無呼吸、レビー小体型認知症、血管性認知症の治療 |
US7423147B2 (en) | 2004-03-31 | 2008-09-09 | Janssen Pharmaceutical, N.V. | Pyridine compounds as histamine H3 modulators |
WO2009063953A1 (ja) | 2007-11-13 | 2009-05-22 | Taisho Pharmaceutical Co., Ltd. | フェニルピラゾール誘導体 |
US7777031B2 (en) | 2006-05-30 | 2010-08-17 | Janssen Pharmaceutica Nv | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor |
US8026360B2 (en) | 2004-09-20 | 2011-09-27 | Xenon Pharmaceuticals Inc. | Substituted pyridazines as stearoyl-CoA desaturase inhibitors |
WO2011149822A1 (en) | 2010-05-26 | 2011-12-01 | Boehringer Ingelheim International Gmbh | 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives |
US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
CN101228127B (zh) * | 2005-05-30 | 2012-05-16 | Msdk.K.公司 | 哌啶衍生物 |
US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
US8883776B2 (en) | 2007-11-20 | 2014-11-11 | Janssen Pharmaceutica N.V. | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor |
US10195196B2 (en) | 2012-08-13 | 2019-02-05 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
US11672799B2 (en) | 2013-07-31 | 2023-06-13 | Novartis Ag | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050119251A1 (en) * | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
CA2580781A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd) |
PE20080360A1 (es) * | 2006-04-20 | 2008-05-22 | Glaxo Group Ltd | Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3 |
JP2009542706A (ja) * | 2006-06-29 | 2009-12-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンh3受容体の置換ベンズアミドモジュレーター |
EP2069312B1 (en) | 2006-07-25 | 2012-11-07 | Cephalon, Inc. | Pyridizinone derivatives |
US20100113776A1 (en) * | 2006-12-14 | 2010-05-06 | Taisho Pharmaceutical Co.,Ltd. | Pyrazole derivative |
JP2010513393A (ja) * | 2006-12-20 | 2010-04-30 | グラクソ グループ リミテッド | H1受容体アンタゴニストとしての4−ベンジル−l(2h)−フタラジノン |
WO2009047336A1 (en) * | 2007-10-11 | 2009-04-16 | Glaxo Group Limited | Phthalazine and pyrido [3,4-d] pyridaz ine compounds as h1 receptor antagonists |
EP2222650A1 (en) * | 2007-11-20 | 2010-09-01 | Janssen Pharmaceutica, N.V. | Substituted pyrazinyl amide compounds as modulators of the histamine h3 receptor |
EP2220045A1 (en) * | 2007-11-20 | 2010-08-25 | Janssen Pharmaceutica, N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
CA2712897A1 (en) | 2008-01-30 | 2009-08-06 | Pharmacopeia, Inc. | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
KR102057877B1 (ko) * | 2012-07-18 | 2019-12-20 | 노스 앤드 사우스 브라더 파마시 인베스트먼트 컴파니 리미티드 | 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도 |
RS60302B1 (sr) | 2016-04-15 | 2020-07-31 | Abbvie Inc | Inhibitori bromodomena |
JP7003394B2 (ja) * | 2016-09-06 | 2022-01-20 | 株式会社村田製作所 | 二次電池用電解液、二次電池、電池パック、電動車両、電力貯蔵システム、電動工具および電子機器 |
US11931345B2 (en) | 2018-05-04 | 2024-03-19 | Cirius Therapeutics, Inc. | Thiazolidinedione analogs for the treatment of NAFLD and metabolic diseases |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060806A2 (en) * | 2000-02-16 | 2001-08-23 | Neurogen Corporation | Substituted arylpyrazines |
WO2001077101A1 (en) * | 2000-04-08 | 2001-10-18 | Astrazeneca Ab | Chemical compounds |
WO2002006223A1 (en) * | 2000-07-13 | 2002-01-24 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
JP2002523413A (ja) * | 1998-08-25 | 2002-07-30 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | ニコチン性アセチルコリン受容体のリガンドとしてのピリジルエーテルおよびチオエーテル、ならびにその治療的用途 |
WO2003024929A1 (en) * | 2001-09-14 | 2003-03-27 | Novo Nordisk A/S | Substituted piperidines with selective binding to histamine h3-receptor |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4330546A (en) * | 1979-09-14 | 1982-05-18 | John Wyeth & Brother Limited | 3-Aryl-3-aryloxypropylamines |
JP2000504336A (ja) * | 1996-02-02 | 2000-04-11 | ゼネカ・リミテッド | 薬学製剤として有用なヘテロ環式化合物 |
JP2001522846A (ja) * | 1997-11-05 | 2001-11-20 | ニューロサーチ、アクティーゼルスカブ | アザ環−エーテル誘導体及びこれをニコチン性achレセプターモジュレーターとして使用する方法 |
WO2002100399A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
SE0102616D0 (sv) * | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
US6673829B2 (en) | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
CA2555402A1 (en) | 2004-02-12 | 2005-09-01 | Celine Bonnefous | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 |
US20080242657A1 (en) * | 2004-03-26 | 2008-10-02 | Marino Michael J | Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists |
WO2006110626A1 (en) | 2005-04-12 | 2006-10-19 | Merck & Co., Inc. | Amidopropoxyphenyl orexin receptor antagonists |
-
2004
- 2004-06-24 CA CA002529790A patent/CA2529790A1/en not_active Abandoned
- 2004-06-24 JP JP2005511807A patent/JP4735261B2/ja not_active Expired - Fee Related
- 2004-06-24 WO PCT/JP2004/009272 patent/WO2005007644A1/ja active Application Filing
- 2004-06-24 US US10/561,115 patent/US7595316B2/en not_active Expired - Lifetime
- 2004-06-24 CN CNA2004800182057A patent/CN1812981A/zh active Pending
- 2004-06-24 AU AU2004257025A patent/AU2004257025B9/en not_active Ceased
- 2004-06-24 EP EP04746741A patent/EP1642898B1/en not_active Expired - Lifetime
-
2009
- 2009-08-13 US US12/540,534 patent/US8044070B2/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002523413A (ja) * | 1998-08-25 | 2002-07-30 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | ニコチン性アセチルコリン受容体のリガンドとしてのピリジルエーテルおよびチオエーテル、ならびにその治療的用途 |
WO2001060806A2 (en) * | 2000-02-16 | 2001-08-23 | Neurogen Corporation | Substituted arylpyrazines |
WO2001077101A1 (en) * | 2000-04-08 | 2001-10-18 | Astrazeneca Ab | Chemical compounds |
WO2002006223A1 (en) * | 2000-07-13 | 2002-01-24 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
WO2003024929A1 (en) * | 2001-09-14 | 2003-03-27 | Novo Nordisk A/S | Substituted piperidines with selective binding to histamine h3-receptor |
Non-Patent Citations (1)
Title |
---|
See also references of EP1642898A4 * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7947718B2 (en) | 2004-03-31 | 2011-05-24 | Janssen Pharmaceutica Nv | Isoxazole compounds as histamine H3 modulators |
US7423147B2 (en) | 2004-03-31 | 2008-09-09 | Janssen Pharmaceutical, N.V. | Pyridine compounds as histamine H3 modulators |
EP1814551A2 (en) * | 2004-09-20 | 2007-08-08 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
JP2008513506A (ja) * | 2004-09-20 | 2008-05-01 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリダジン誘導体 |
US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US8026360B2 (en) | 2004-09-20 | 2011-09-27 | Xenon Pharmaceuticals Inc. | Substituted pyridazines as stearoyl-CoA desaturase inhibitors |
EP2316458A1 (en) * | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
WO2006059778A1 (ja) * | 2004-12-01 | 2006-06-08 | Banyu Pharmaceutical Co., Ltd. | 置換ピリドン誘導体 |
JP2016106142A (ja) * | 2005-04-01 | 2016-06-16 | ビオポロジェ | 非イミダゾールアルキルアミンヒスタミンh3−受容体リガンドによるパーキンソン病、閉塞性睡眠時無呼吸、レビー小体型認知症、血管性認知症の治療 |
JP2008534572A (ja) * | 2005-04-01 | 2008-08-28 | ビオポロジェ | 非イミダゾールアルキルアミンヒスタミンh3−受容体リガンドによるパーキンソン病、閉塞性睡眠時無呼吸、レビー小体型認知症、血管性認知症の治療 |
JP2014062126A (ja) * | 2005-04-01 | 2014-04-10 | Bioprojet | 非イミダゾールアルキルアミンヒスタミンh3−受容体リガンドによるパーキンソン病、閉塞性睡眠時無呼吸、レビー小体型認知症、血管性認知症の治療 |
KR101397913B1 (ko) * | 2005-05-30 | 2014-05-26 | 엠에스디 가부시키가이샤 | 신규 피페리딘 유도체 |
JP5154927B2 (ja) * | 2005-05-30 | 2013-02-27 | Msd株式会社 | 新規ピペリジン誘導体 |
WO2006129826A1 (ja) * | 2005-05-30 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
RU2417985C2 (ru) * | 2005-05-30 | 2011-05-10 | Баниу Фармасьютикал Ко., Лтд. | Новые производные пиперидина |
US8138206B2 (en) | 2005-05-30 | 2012-03-20 | Msd. K.K. | Piperidine derivative |
CN101228127B (zh) * | 2005-05-30 | 2012-05-16 | Msdk.K.公司 | 哌啶衍生物 |
US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
US8637520B2 (en) | 2006-05-30 | 2014-01-28 | Janssen Pharmaceutica Nv | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor |
US9321729B2 (en) | 2006-05-30 | 2016-04-26 | Janssen Pharmaceutica Nv | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor |
US7777031B2 (en) | 2006-05-30 | 2010-08-17 | Janssen Pharmaceutica Nv | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor |
US8940731B2 (en) | 2006-05-30 | 2015-01-27 | Janssen Pharmaceutica Nv | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor |
WO2008072703A1 (ja) * | 2006-12-14 | 2008-06-19 | Taisho Pharmaceutical Co., Ltd. | ビフェニルアミド誘導体 |
US8183387B2 (en) | 2007-11-13 | 2012-05-22 | Taisho Pharmaceutical Co., Ltd | Phenylpyrazole derivatives |
US7888354B2 (en) | 2007-11-13 | 2011-02-15 | Taisho Pharmaceutical Co., Ltd | Phenylpyrazole derivatives |
WO2009063953A1 (ja) | 2007-11-13 | 2009-05-22 | Taisho Pharmaceutical Co., Ltd. | フェニルピラゾール誘導体 |
US8193176B2 (en) | 2007-11-13 | 2012-06-05 | Taisho Pharmaceutical Co., Ltd | Phenylpyrazole derivatives |
US8883776B2 (en) | 2007-11-20 | 2014-11-11 | Janssen Pharmaceutica N.V. | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor |
WO2011149822A1 (en) | 2010-05-26 | 2011-12-01 | Boehringer Ingelheim International Gmbh | 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives |
US10195196B2 (en) | 2012-08-13 | 2019-02-05 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
US10758533B2 (en) | 2012-08-13 | 2020-09-01 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
US11229648B2 (en) | 2012-08-13 | 2022-01-25 | Novartis Ag | 1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions |
US11672799B2 (en) | 2013-07-31 | 2023-06-13 | Novartis Ag | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions |
Also Published As
Publication number | Publication date |
---|---|
US20100210637A1 (en) | 2010-08-19 |
CA2529790A1 (en) | 2005-01-27 |
US7595316B2 (en) | 2009-09-29 |
AU2004257025A1 (en) | 2005-01-27 |
EP1642898A4 (en) | 2009-03-18 |
AU2004257025B2 (en) | 2010-01-28 |
EP1642898B1 (en) | 2013-03-27 |
CN1812981A (zh) | 2006-08-02 |
JP4735261B2 (ja) | 2011-07-27 |
EP1642898A1 (en) | 2006-04-05 |
US20060178375A1 (en) | 2006-08-10 |
AU2004257025B9 (en) | 2010-05-27 |
JPWO2005007644A1 (ja) | 2006-08-31 |
US8044070B2 (en) | 2011-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4735261B2 (ja) | ヘテロアリールオキシ含窒素飽和ヘテロ環誘導体 | |
JP4765627B2 (ja) | 新規ピペリジン誘導体 | |
EP1717230B1 (en) | Fused-ring 4-oxopyrimidine derivative | |
EP1553089B1 (en) | Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | |
CN1960977B (zh) | 喹唑啉衍生物 | |
WO2005085200A1 (ja) | ピリドン誘導体 | |
WO2009154132A1 (ja) | スピロジアミン-ジアリールケトオキシム誘導体 | |
JP2011178806A (ja) | 含窒素縮合ヘテロ芳香環誘導体 | |
WO2007018248A9 (ja) | ピリドン化合物 | |
WO2004103992A1 (ja) | 2-アミノキノリン誘導体 | |
AU2005310467B2 (en) | Substituted pyridone derivative | |
MXPA06009244A (en) | Fused-ring 4-oxopyrimidine derivative | |
JPWO2010013595A1 (ja) | 5員−5員又は5員−6員縮環シクロアルキルアミン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005511807 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2006178375 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10561115 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2529790 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5950/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004746741 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048182057 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004257025 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004257025 Country of ref document: AU Date of ref document: 20040624 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004257025 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004746741 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10561115 Country of ref document: US |